0001628280-21-016106 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2021	Jul. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	000-50644
Entity Registrant Name	Cutera, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0492262
Entity Address, Address Line One	3240 Bayshore Blvd.
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	415
Local Phone Number	657-5500
Title of 12(b) Security	Common Stock ($0.001 par value)
Trading Symbol	CUTR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,942,446
Entity Central Index Key	0001162461
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 169,200	$ 47,047
Accounts receivable, net of allowance for credit losses of $1,639 and $1,598, respectively	25,903	21,962
Inventories	34,591	28,508
Other current assets and prepaid expenses	8,856	8,779
Total current assets	238,550	106,296
Property and equipment, net	2,148	2,299
Deferred tax asset	592	643
Operating lease right-of-use assets	15,919	17,076
Goodwill	1,339	1,339
Other long-term assets	5,615	5,080
Total assets	264,163	132,733
Current liabilities:
Accounts payable	6,210	6,684
Accrued liabilities	41,343	31,079
Operating lease liabilities	2,422	2,260
PPP loan payable	0	3,630
Extended warranty liability	649	1,216
Deferred revenue	9,695	9,489
Total current liabilities	60,319	54,358
Deferred revenue, net of current portion	1,708	1,748
Operating lease liabilities, net of current portion	14,705	15,950
PPP loan payable, net of current portion	0	3,555
Convertible notes, net of unamortized debt issuance costs of $4,450	133,800	0
Other long-term liabilities	288	242
Total liabilities	210,820	75,853
Commitments and Contingencies (Notes 12)
Stockholders’ equity:
Common stock, $0.001 par value; authorized: 50,000,000 shares; issued and outstanding: 17,933,020 and 17,679,232 shares at June 30, 2021 and December 31, 2020, respectively	18	18
Additional paid-in capital	106,173	117,097
Accumulated deficit	(52,848)	(60,235)
Total stockholders’ equity	53,343	56,880
Total liabilities and stockholders’ equity	$ 264,163	$ 132,733

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for credit loss, current	$ 1,639	$ 1,598
Unamortized debt issuance costs	$ 4,450
Common stock, par value (USD per share)	$ 0.001	$ 0.001
Common stock authorized (in shares)	50,000,000	50,000,000
Common stock issued (in shares)	17,933,020	17,679,232
Common stock outstanding (in shares)	17,933,020	17,679,232

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net revenue:
Total net revenue	$ 58,589	$ 26,369	$ 108,257	$ 58,608
Cost of revenue:
Total cost of revenue	24,800	14,745	46,758	32,648
Gross profit	33,789	11,624	61,499	25,960
Operating expenses:
Sales and marketing	18,410	11,035	33,478	25,823
Research and development	4,850	2,991	8,962	6,862
General and administrative	8,461	8,529	15,826	16,336
Total operating expenses	31,721	22,555	58,266	49,021
Income (loss) from operations	2,068	(10,931)	3,233	(23,061)
Interest and other income (expense), net:
Amortization of debt issuance costs	(215)	0	(267)	0
Interest on convertible notes	(778)	0	(969)	0
Gain on extinguishment of PPP loan	7,185	0	7,185	0
Other income (expense), net	(392)	3	(1,415)	(204)
Total interest and other income (expense), net	5,800	3	4,534	(204)
Income (loss) before income taxes	7,868	(10,928)	7,767	(23,265)
Income tax expense	122	466	380	543
Net income (loss)	$ 7,746	$ (11,394)	$ 7,387	$ (23,808)
Net income (loss) per share:
Basic (USD per share)	$ 0.43	$ (0.67)	$ 0.41	$ (1.51)
Diluted (USD per share)	$ 0.39	$ (0.67)	$ 0.40	$ (1.51)
Weighted-average number of shares used in per share calculations:
Basic (in shares)	17,862	17,055	17,815	15,744
Diluted (in shares)	22,453	17,055	20,855	15,744
Total product revenue
Net revenue:
Total net revenue	$ 51,812	$ 21,745	$ 95,363	$ 48,136
Cost of revenue:
Total cost of revenue	20,893	12,206	39,224	26,309
Service
Net revenue:
Total net revenue	6,777	4,624	12,894	10,472
Cost of revenue:
Total cost of revenue	$ 3,907	$ 2,539	$ 7,534	$ 6,339

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 7,746	$ (11,394)	$ 7,387	$ (23,808)
Available-for-sale investments
Reclassification adjustment for losses on investments recognized during the period	0	2	0	63
Net change in unrealized gain on available-for-sale investments	0	2	0	63
Other comprehensive gain, net of tax	0	2	0	63
Comprehensive income (loss)	$ 7,746	$ (11,392)	$ 7,387	$ (23,745)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Consolidated Statements of Changes In Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income (loss)
Balance (in shares) at Dec. 31, 2019		14,315,586
Balance at Dec. 31, 2019	$ 45,942	$ 14	$ 82,346	$ (36,358)	$ (60)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for employee purchase plan (in shares)		39,248
Issuance of common stock for employee purchase plan	437		437
Exercise of stock options (in shares)		46,128
Exercise of stock options	411		411
Issuance of common stock in settlement of restricted and performance stock unites, net of shares withheld for employee taxes (in shares)		423,976
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes	(3,117)	$ 1	(3,118)
Issuance of common stock in connection with public offering, net of offering cost of $2,303 (in shares)		2,742,750
Issuance of common stock in connection with public offering, net of offering cost of $2,303	26,496	$ 3	26,493
Stock-based compensation expense	6,075		6,075
Net income (loss)	(23,808)			(23,808)
Net change in unrealized loss on available-for-sale investments	63				63
Balance (in shares) at Jun. 30, 2020		17,567,688
Balance at Jun. 30, 2020	52,499	$ 18	112,644	(60,166)	3
Balance (in shares) at Mar. 31, 2020		14,578,146
Balance at Mar. 31, 2020	33,536	$ 15	82,292	(48,772)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for employee purchase plan (in shares)		39,248
Issuance of common stock for employee purchase plan	437		437
Exercise of stock options (in shares)		23,837
Exercise of stock options	210		210
Issuance of common stock in settlement of restricted and performance stock unites, net of shares withheld for employee taxes (in shares)		183,707
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes	(883)	$ 0	(883)
Issuance of common stock in connection with public offering, net of offering cost of $2,303 (in shares)		2,742,750
Issuance of common stock in connection with public offering, net of offering cost of $2,303	26,496	$ 3	26,493
Stock-based compensation expense	4,095		4,095
Net income (loss)	(11,394)			(11,394)
Net change in unrealized loss on available-for-sale investments	2				2
Balance (in shares) at Jun. 30, 2020		17,567,688
Balance at Jun. 30, 2020	$ 52,499	$ 18	112,644	(60,166)	3
Balance (in shares) at Dec. 31, 2020	17,679,232	17,679,232
Balance at Dec. 31, 2020	$ 56,880	$ 18	117,097	(60,235)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for employee purchase plan (in shares)		38,991
Issuance of common stock for employee purchase plan	$ 645		645
Exercise of stock options (in shares)	53,598	53,598
Exercise of stock options	$ 1,252		1,252
Purchase of capped call	(16,134)		(16,134)
Issuance of common stock in settlement of restricted and performance stock unites, net of shares withheld for employee taxes (in shares)		161,199
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes	(1,452)		(1,452)
Stock-based compensation expense	4,765		4,765
Net income (loss)	7,387			7,387
Net change in unrealized loss on available-for-sale investments	$ 0
Balance (in shares) at Jun. 30, 2021	17,933,020	17,933,020
Balance at Jun. 30, 2021	$ 53,343	$ 18	106,173	(52,848)	0
Balance (in shares) at Mar. 31, 2021		17,801,926
Balance at Mar. 31, 2021	41,630	$ 18	102,206	(60,594)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for employee purchase plan (in shares)		38,991
Issuance of common stock for employee purchase plan	645		645
Exercise of stock options (in shares)		29,508
Exercise of stock options	856		856
Issuance of common stock in settlement of restricted and performance stock unites, net of shares withheld for employee taxes (in shares)		62,595
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes	(453)		(453)
Stock-based compensation expense	2,919		2,919
Net income (loss)	7,746			7,746
Net change in unrealized loss on available-for-sale investments	$ 0
Balance (in shares) at Jun. 30, 2021	17,933,020	17,933,020
Balance at Jun. 30, 2021	$ 53,343	$ 18	$ 106,173	$ (52,848)	$ 0

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net income (loss)	$ 7,387	$ (23,808)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation	4,765	6,075
Depreciation and amortization	707	715
Amortization of contract acquisition costs	1,003	1,392
Amortization of debt issuance costs	267	0
Impairment of capitalized cloud computing costs	182	805
Change in deferred tax asset	51	4
Allowance for credit losses	492	1,696
Gain on sale of property and equipment	(82)	0
Gain on extinguishment of PPP loan	(7,185)	0
Change in right-of-use assets	604	0
Other	0	198
Changes in assets and liabilities:
Accounts receivable	(4,433)	6,034
Inventories	(5,958)	2,681
Other current assets and prepaid expenses	(77)	316
Other long-term assets	(1,720)	(519)
Accounts payable	(474)	(1,004)
Accrued liabilities	10,220	(9,754)
Extended warranty liabilities	(567)	(339)
Operating lease liabilities	(530)	0
Deferred revenue	166	(2,443)
Net cash provided by (used in) operating activities	4,818	(17,951)
Cash flows from investing activities:
Acquisition of property, equipment, and software	(370)	(435)
Proceeds from disposal of property and equipment	71	0
Proceeds from maturities of marketable investments	0	10,900
Purchase of marketable investments	0	(16,167)
Net cash used in investing activities	(299)	(5,702)
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan	1,897	848
Purchase of capped call	(16,134)	0
Proceeds from issuance of Convertible notes	138,250	7,149
Payment of issuance costs of Convertible notes	(4,717)	0
Proceeds from equity offering	0	28,799
Cost of equity offering	0	(2,303)
Taxes paid related to net share settlement of equity awards	(1,451)	(3,117)
Payments on finance lease obligations	(211)	(380)
Net cash provided by financing activities	117,634	30,996
Net increase in cash and cash equivalents	122,153	7,343
Cash and cash equivalents at beginning of period	47,047	26,316
Cash and cash equivalents at end of period	169,200	33,659
Supplemental disclosure of non-cash items:
Assets acquired under finance lease	25	27
Assets acquired under operating lease	123	1,169
Gain on extinguishment of PPP loan	7,185	0
Debt issuance costs accrued	452	0
Supplemental disclosure of cash flow information:
Income tax paid	$ 458	$ 0

Consolidated Statements of Changes In Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Common Stock
Stock issued, offering cost	$ 2,303	$ 2,303

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Description of Operations and Principles of Consolidation Cutera, Inc. (“Cutera” or the “Company”) provides energy-based aesthetic systems for practitioners worldwide. The Company develops, manufactures, distributes, and markets energy-based product platforms for use by physicians and other qualified practitioners, enabling them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following system platforms: enlighten, excel, Secret PRO, Juliet, Secret RF, truSculpt and xeo. Several of the Company’s systems offer multiple hand pieces and applications, providing customers the flexibility to upgrade their systems. The sales of (i) systems, system upgrades, and hand pieces (collectively “Systems” revenue); (ii) replacement hand pieces, Titan, truSculpt 3D,truSculpt iD and truSculpt flex cycle refills, as well as single use disposable tips applicable to Secret PRO, Juliet and Secret RF (“Consumables” revenue); (iii) the distribution of third party manufactured skincare products (“Skincare” revenue); and (iv) the leasing of equipment through a membership program; are collectively classified as “Products” revenue. In addition to Products revenue, the Company generates revenue from the sale of post-warranty service contracts, parts, detachable hand piece replacements (except for Titan, truSculpt 3D, truSculpt iD and truSculpt flex) and service labor for the repair and maintenance of products that are out of warranty, all of which are collectively classified as “Service” revenue. The Company’s corporate headquarters and U.S. operations are located in Brisbane, California, where the Company conducts manufacturing, warehousing, research and development, regulatory, sales and marketing, service, and administrative activities. The Company also maintains regional distribution centers (“RDCs”) in select locations across the U.S. These RDCs serve as forward warehousing for systems and service parts in various geographies. The Company markets, sells and services its products through its sales and service employees in North America (including Canada), Australia, Austria, Belgium, France, Germany, Hong Kong, Japan, Spain, Switzerland, and the United Kingdom. Sales and services outside of these direct markets are made through a worldwide distributor network in over 42 countries. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Basis of Presentation In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements included in this report reflect all adjustments necessary for a fair statement of its condensed consolidated statements of financial position as of June 30, 2021 and December 31, 2020, and its condensed consolidated statements of results of operations, comprehensive income (loss), changes in equity, and cash flows for the three and six months ended June 30, 2021, and 2020. The December 31, 2020 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The results for interim periods are not necessarily indicative of results for the entire year or any other interim period. Presentation of certain prior year balances have been updated to conform with current year presentation. All significant intercompany accounts and transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s previously filed audited financial statements and the related notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2021. Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, stability of global financial markets, cybersecurity breaches and other disruptions that could compromise the Company’s information or results, business disruptions that are caused by natural disasters or pandemic events, management of international activities, competition from substitute products and larger companies, ability to obtain and maintain regulatory approvals, government regulations and oversight, patent and other types of litigation, ability to protect proprietary technology from counterfeit versions of the Company's products, strategic relationships and dependence on key individuals. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The COVID-19 outbreak has negatively affected the United States and global economies. Though the economy is gradually recovering as of the second quarter of 2021, the timing and extent of a full global economic recovery is still uncertain. The spread of the coronavirus and the Delta variant in particular, has impacted the global economy broadly in 2020, including restrictions on travel, shifting work forces to work remotely and quarantine policies put into place by businesses and governments, had a material economic effect on the Company’s business during the year ended December 31, 2020 and in the six months ended June 30, 2021. Healthcare facilities in many countries effectively banned elective procedures and this had a significant impact on the Company. Many of the Company’s products are used in aesthetic elective procedures and as such, the bans on elective procedures substantially reduced the Company’s sales and marketing efforts in the early months of the pandemic and led the Company to implement cost control measures. Although the Company’s revenues and profits have improved compared to the first half of fiscal 2020 and the overall economic outlook has also improved in 2021, the COVID-19 outbreak continues to be fluid especially in light of the Delta variant, and the long-term impact on the Company's business due to COVID-19 is still uncertain. The Company cannot presently predict the scope and severity of any impacts in future periods from business shutdowns or disruptions due to the COVID-19 pandemic, but the impact on economic activity including the possibility of recession or financial market instability could have a material adverse effect on the Company’s business, revenue, operating results, cash flows and financial condition. The Company continues to assess whether any impairment of its goodwill or its long-lived assets has occurred and has determined that no charges, other than an impairment loss of $0.2 million on capitalized implementation costs of cloud-based customer relationship management (“CRM”) software occurred were necessary during the six months ended June 30, 2021. The Company will continue to monitor future conditions important to its assessment of potential impairment of its long-lived assets and goodwill, including the impacts of the COVID–19 pandemic and other ongoing impacts which are subject to uncertainty. The Company has experienced a significant increase in sales of skincare products under the exclusive distribution agreement with ZO Skin Health, Inc. (“ZO”), which allows the Company to sell ZO’s skincare products in Japan. The reason for the increase in skincare products sales may have been the result of changes in customers’ spending habits as customers purchased more aesthetic treatments that were able to be applied at home, due to limitations on in-person aesthetic procedures, social distancing and mask wearing requirements due to the COVID-19 pandemic. Future growth in sales of skincare products depends on customers’ spending habits, which may revert to original spending habits after the COVID-19 pandemic. Such changes may have a material adverse effect on the Company’s revenue, operating results, and cash flows. Accounting Policies These unaudited condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC applicable to interim financial statements. While these statements reflect all normal recurring adjustments that are, in the opinion of management, necessary for fair presentation of the results of the interim period, they do not include all of the information and footnotes required by GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the financial statement disclosures in its annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 23, 2021. The Company uses the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the notes to condensed consolidated financial statements refer to the Company’s continuing operations. Note 13 provides information about the Company’s adoption of the new accounting standard for debt with conversion and other options, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. The Company issued $138.3 million of convertible senior notes ("Notes" or "Convertible notes") in a private placement offering on March 5, 2021. The Convertible notes bear interest at a rate of 2.25% per year. In accordance with Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-6, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), the Company recorded the Convertible notes as long-term debt with no separation between the Convertible notes and the conversion option. Each reporting period, the Company will determine whether any criteria is met for the note holders to have the option to redeem the Convertible notes early, which will result in a change in the classification of the Convertible notes to current liabilities. The circumstances described in the paragraph above were met during the second quarter of 2021 as the Company's stock traded at a price in excess of the conversion price, and as a result, the Notes are convertible at the option of the holder from July 1, 2021 until September 30, 2021. Upon any conversion of the Convertible notes, the Company would be required to pay or deliver, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at the Company’s election. To the extent there are any conversions during the period from July 1, 2021 until September 30, 2021, the Company intends to settle such conversions by issuing shares of common stock; therefore, as of June 30, 2021, the Convertible notes have been included as long term liability on the condensed consolidated balance sheet. The costs associated with issuance of the Convertible notes, including underwriters’ fees, are presented in the condensed consolidated balance sheet as a direct deduction from the carrying amount of the Convertible notes. The debt issuance costs are being amortized over the life of the Convertible notes as additional non-cash interest expense. In connection with issuance of the Convertible notes, the Company entered into capped call transactions with certain option counterparties. The capped call transactions are generally designated to reduce the potential dilution of the Company's common stock upon any conversion of the Notes. The capped calls were purchased for $16.1 million and recorded as a reduction to additional paid in capital in the condensed consolidated balance sheet as of June 30, 2021. The Company capitalized cloud computing systems implementation costs of $0.6 million during the three months ending June 30, 2021. These costs relate to an on-going implementation of a new Enterprise Resource Planning system and are included in Other long-term assets and Other current assets and prepaid expenses on the condensed consolidated balance sheet. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates. On an ongoing basis, management evaluates its estimates, including those related to warranty obligations, sales commission, allowance for credit losses, sales allowances, valuation of inventories, fair value of goodwill, useful lives of property and equipment, impairment testing for long-lived-assets, implicit and incremental borrowing rates related to the Company’s leases, variables used in calculating the fair value of the Company's equity awards, expected achievement of performance based vesting criteria, management performance bonuses, assumptions used in operating and sales-type lease classification, the standalone selling price of the Company's products and services, the period of benefit used to capitalize and amortize contract acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, residual value of leased equipment, lease term and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes, to remove certain exceptions and improve consistency of application, including, among other things, requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company adopted this guidance in the three and six months ended June 30, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial position and results of operations. In August 2020, the FASB issued ASU No. 2020-6, Debt – Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815), to simplify the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the amendment, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the computation of diluted earnings per share. The Company early adopted the guidance on a prospective basis effective January 1, 2021. See Note 13 – Debt.

Cash, Cash Equivalents

6 Months Ended

Jun. 30, 2021

Cash and Cash Equivalents [Abstract]

Cash, Cash Equivalents

The following table summarizes the Company's cash and cash equivalents (in thousands):


(Dollars in thousands)	June 30, 2021		December 31, 2020
Cash and cash equivalents	$	169,200	$	47,047

The Company had no marketable securities as of June 30, 2021 and December 31, 2020.

Fair Value of Financial Instruments	6 Months Ended
Fair Value of Financial Instruments	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures certain financial assets at fair value, including cash and cash equivalents. The fair value hierarchy contains the following three levels of inputs that may be used to measure fair value, in accordance with ASC 820: •Level 1: inputs, which include quoted prices in active markets for identical assets or liabilities; •Level 2: inputs, which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and •Level 3: inputs, which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies, or similar valuation techniques, as well as significant management judgment or estimation. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considering counterparty credit risk in its assessment of fair value. See Note 13 - Debt for the carrying amount and estimated fair value of the Company’s Convertible notes due 2026.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Balance Sheet Details

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Details

Inventories

As of June 30, 2021 and December 31, 2020, inventories consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Raw materials	$	15,862	$	14,874
Work in process	1,145		1,030
Finished goods	17,584		12,604
Total	$	34,591	$	28,508

Accrued Liabilities

As of June 30, 2021 and December 31, 2020, accrued liabilities consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Accrued payroll and related expenses	$	16,427	$	12,197
Sales and marketing accruals	3,124		2,352
Accrued inventory in transit	4,469		2,476
Product warranty	3,789		2,908
Accrued sales tax	5,439		5,343
Other accrued liabilities	8,095		5,803
Total	$	41,343	$	31,079

Product Remediation Liability

During the fourth quarter of 2018, the Company recognized a liability for a product remediation plan related to one of its legacy systems. This was related to a voluntary action initiated by the Company to replace a component in one of the Company’s

legacy products. The remediation plan consists primarily of replacement of a component in the system. The accrued liability consisted of the estimated cost of materials and labor to replace the component in all units that were under the Company's standard warranty or were covered under the existing extended warranty contracts. The Company recorded a liability of approximately $5.0 million in 2018.

As of June 30, 2021 and December 31, 2020, approximately $0.3 million of the total product remediation liability balance was recorded as a component of the Company’s product warranty and included in accrued liabilities, and $0.7 million and $1.2 million, respectively, was separately recorded as extended warranty liability.

During the three and six months ended June 30, 2021, the Company recorded $0.1 million and $0.2 million, respectively, of excess reserve related to extended warranty and product warranty. Total costs incurred (including excess reversals) related to product warranty and extended warranty liability during the three and six months ended June 30, 2021 were $0.1 million and $0.5 million, respectively. Total costs incurred related to product warranty and extended warranty liability during the three and six months ended June 30, 2020 were Nil and $0.3 million, respectively.

Warranty and Extended Service Contract

6 Months Ended

Jun. 30, 2021

Product Warranties Disclosures [Abstract]

Warranty and Extended Service Contract

The Company has a direct field service organization in North America (including Canada). Internationally, the Company provides direct service support in Australia, Belgium, France, Germany, Hong Kong, Japan, Spain, Switzerland, and the United Kingdom. In several other countries, where the Company does not have a direct presence, the Company provides service through a network of distributors and third-party service providers.

After the original warranty period, maintenance and support are offered on an extended service contract basis or on a time and materials basis. The Company provides for the estimated cost to repair or replace products under standard warranty at the time of sale. Costs incurred in connection with extended service contracts are recognized at the time when costs are incurred, except for a one-time extended service contracts charge of $3.2 million recorded in the year ended December 31, 2018 related to the cost to replace a component in one of the Company's legacy products.

The following table provides the changes in the product warranty accrual for the three and six months ended June 30, 2021 and 2020 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020 (1)		2021		2020 (1)
Beginning Balance	$	3,351	$	3,398	$	2,908	$	4,401
Add: Accruals for warranties issued during the period	2,210		1,100		3,735		1,960
Less: Settlements made during the period	(1,772)		(1,343)		(2,854)		(3,206)
Ending Balance	$	3,789	$	3,155	$	3,789	$	3,155

(1)The ending product warranty accrual balance excludes 0.6 million and 1.7 million as of June 30, 2021 and 2020, respectively, related to one-time extended service contracts costs to replace components in one of the Company’s legacy products.

The $1.8 million and $2.9 million of settlements made in the three and six months ended June 30, 2021, and $1.3 million and $3.2 million made in the three and six months ended June 30, 2020, respectively, exclude costs related to extended service contract cost of $0.1 million and $0.3 million in the respective periods, incurred to replace a component in one of the Company's legacy products.

Deferred Revenue

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Deferred Revenue

The Company records deferred revenue when revenue is to be recognized subsequent to invoicing. For extended service contracts, the Company generally invoices customers at the beginning of the extended service contract term. The Company’s extended service contracts typically have one, two or three year terms. Deferred revenue also includes payments for training and extended marketing support service. Approximately 84% of the Company’s deferred revenue balance of $11.4 million as of June 30, 2021 will be recognized over the next 12 months.

The following table provides changes in the deferred revenue balance for the three and six months ended June 30, 2021 and 2020 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Beginning balance	$	11,737	$	12,969	$	11,237	$	14,222
Add: Payments received	4,423		2,554		9,352		6,125
Less: Revenue	(1,834)		(1,107)		(2,279)		(1,699)
Less: Revenue included in the beginning balance and recognized as revenue in the current quarter	(2,923)		(2,637)		(6,907)		(6,869)
Ending balance	$	11,403	$	11,779	$	11,403	$	11,779

Costs for extended service contracts were $2.2 million and $4.2 million for the three and six months ended June 30, 2021, respectively, and were $2.3 million and $3.5 million for the three and six months ended June 30, 2020, respectively.

Revenue	6 Months Ended
Revenue	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company’s performance obligations are satisfied either over time or at a point in time. Revenue from performance obligations that are transferred to customers over time accounted for approximately 12% of the Company's total revenue for the three months ended June 30, 2021 and 2020, and 18% of the Company's total revenue for the six months ended June 30, 2021 and 2020. The Company has certain system sale arrangements that contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct. The Company’s products and services are distinct if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer, and if the Company’s promise to transfer the products or service to the customer is separately identifiable from other promises in the sale arrangements. The Company’s system sale arrangements can include all or a combination of the following performance obligations: the system and software license (considered as one performance obligation), system accessories (hand pieces), training, other accessories, extended service contracts, marketing services, and time and materials services. For the Company’s system sale arrangements that include an extended service contract, the period of service commences at the expiration of the Company’s standard warranty offered at the time of the system sale. The Company considers the extended service contracts terms in the arrangements that are legally enforceable to be performance obligations. Other than extended service contracts and marketing services, which are satisfied over time, the Company generally satisfies all performance obligations at a point in time. Systems, system accessories (hand pieces), service contracts, training, and time and materials services are also sold on a stand-alone basis, and these performance obligations are satisfied at a point in time. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price basis. Significant Judgments The determination of whether two or more contracts entered into at or near the same time with the same customer should be combined and accounted for as one contract may require the use of significant judgment. In making this determination, the Company considers whether the contracts are negotiated as a package with a single commercial objective, have price interdependencies, or promise goods or services that represent a single performance obligation. While the Company’s purchase agreements do not provide customers with a contractual right of return, the Company maintains a sales allowance to account for potential returns or refunds as a reduction in transaction price at the time of sale. The Company estimates sales returns and other variable consideration based on historical experience. The Company determines the standalone selling price ("SSP") for each performance obligation as follows: •Systems: The SSPs for systems are based on directly observable sales in similar circumstances to similar customers. •Extended warranty/Service contracts: SSP is based on observable price when sold on a standalone basis (by customer type). Nature of Products and Services Systems Systems revenue is generated from the sale of systems and from the sale of upgrades to existing systems. A system consists of a console that incorporates a universal graphic user interface, a laser or other energy-based module, control system software and high voltage electronics, as well as one or more hand pieces. In certain applications, the laser or other energy-based module is contained in the hand piece, such as with the Company’s Pearl and Pearl Fractional applications, rather than within the console. The Company offers customers the ability to select the system that best fits their practice at the time of purchase and then to cost-effectively add applications to their system as their practice grows. This provides customers the flexibility to upgrade their systems whenever they choose and provides the Company with a source of additional Systems revenue. The system or upgrade and the right to use the embedded software represent a single performance obligation as the software license is integral to the functionality of the system or upgrade. For systems sold directly to end-customers that are credit approved, revenue is recognized when the Company transfers control to the end-customer, which occurs when the product is shipped to the customer or when the customer receives the product, depending on the nature of the arrangement. When collectability is not established in advance of receipt of payment from the customer, revenue is recognized upon the later of the receipt of payment or the satisfaction of the performance obligation. For systems sold through credit approved distributors, revenue is recognized upon shipment to the distributor. The Company typically receives payment for its system consoles and other accessories within 30 days of shipment. Certain international distributor arrangements allow for longer payment terms. Skincare products The Company sells third-party manufactured skincare products in Japan. The skincare products are purchased from a third-party manufacturer and sold to medical offices and licensed physicians. The Company warrants that the skincare products are free of significant defects in workmanship and materials for 90 days from shipment. These are typically sold in a separate contract as the only performance obligations. The Company acts as the principal in this arrangement, as the Company determines the price to charge customers for the skincare products and controls the products before they are transferred to the customer. The Company recognizes revenue for skincare products upon shipment. Consumables and other accessories The Company classifies its customers' purchases of replacement cycles for truSculpt iD and truSculpt flex, as well as replacement hand pieces, Titan and truSculpt 3D hand pieces, and single use disposable tips applicable to Secret PRO, Juliet, and Secret RF, as Consumable revenue, which provides the Company with a source of recurring revenue from existing customers. The Juliet and Secret RF products' single use disposable tips must be replaced after every treatment. Sales of these consumable tips further enhance the Company’s recurring revenue. The Company’s systems offer multiple hand pieces and applications, which allow customers to upgrade their systems. Equipment leasing The Company leases equipment to customers through membership programs and receives a fixed monthly fee over the term of the arrangement. The Company classifies its lease income as product revenue. The Company recognizes lease income over the term of the lease if the lease is classified as an operating lease. For agreements that grant customers the right to purchase the leased system, the Company typically classifies the lease as a sales-type lease as the Company has determined it is reasonably certain that the customer will exercise the purchase option. On the commencement of sales-type leases, the Company recognizes revenue upfront in product revenue and the corresponding receivables recorded in other current assets and prepaid expenses on the condensed consolidated balance sheets (See Note 11 - Leases). There was no revenue recognized for sales-type leases for the three and six months ended June 30, 2021 or 2020. Revenue from equipment leases, which was accounted for as operating leases, was not material for the three and six months ended June 30, 2021 or 2020. Extended contract services The Company offers post-warranty services to its customers through extended service contracts that cover parts and labor for terms of one, two, or three years. Service contract revenue is recognized over time, using a time-based measure of progress, as customers benefit from the service throughout the service period. The Company also offers services on a time-and-materials basis for systems and detachable hand piece replacements. Revenue related to services performed on a time-and-materials basis is recognized when performed. These post-warranty services serve as additional sources of recurring revenue from the Company’s installed product base. Training Sales of systems to customers include training on the use of the system to be provided within 180 days of purchase. The Company considers training a separate performance obligation as customers can immediately benefit from the training together with the customer’s system. Training is also sold separately from systems. The Company recognizes revenue for training when the training is provided. Training is not required for customers to use the systems. Customer Marketing Support In North America, the Company offers marketing and consulting phone support to its customers across all system platforms. These customer marketing support services include a practice development model and marketing training, performed remotely with ongoing phone consultations for six months from date of purchase. The Company considers customer marketing support a separate performance obligation, and recognizes revenue over the six-month term of the contracts. Loyalty Program The Company has a customer loyalty program for qualified customers located in the U.S. and Canada. Under the loyalty program, based on their purchasing levels, customers accumulate points that can be redeemed for such rewards as the right to attend the Company’s advanced training event for truSculpt, or a ticket for the Company’s annual forum. A customer’s account must be in good standing to receive the benefits of the rewards program. Rewards are earned on a quarterly basis and must be used in the following quarter. All unused rewards are forfeited. The fair value of the reward earned by loyalty program members is included in accrued liabilities and recorded as a reduction of net revenue at the time the reward is earned. As of June 30, 2021 and December 31, 2020, the liability for the loyalty program included in accrued liabilities was $0.6 million and $0.3 million, respectively. Deferred Sales Commissions Incremental costs of obtaining a contract, which consist primarily of commissions and related payroll taxes, are capitalized and amortized on a straight-line basis over the expected period of benefit, except for costs that are recognized when product is sold. The Company uses the portfolio method to recognize the amortization expense related to these capitalized costs related to initial contracts and such expense is recognized over a period associated with the revenue of the related portfolio, which is generally two to three years. Total capitalized costs as of June 30, 2021 and December 31, 2020 were $3.6 million and $3.4 million, respectively, and are included in Other long-term assets in the Company’s condensed consolidated balance sheet. Amortization expense for these assets was $0.5 million and $1.0 million during the three and six months ended June 30, 2021, respectively, and was $0.7 million and $1.4 million during the three and six months ended June 30, 2020, respectively. The amortization related to these capitalized costs is included in sales and marketing expense in the Company’s condensed consolidated statement of operations.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Stockholders' Equity and Stock-based Compensation Expense

6 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Stockholders' Equity and Stock-based Compensation Expense

Stockholders’ Equity and Stock-based Compensation Expense

The Company’s equity incentive plans are broad-based, long-term programs intended to attract and retain talented employees and align stockholder and employee interests. In June 2019, stockholders approved an amendment and restatement of the Amended and Restated 2004 Equity Incentive Plan as the 2019 Equity Incentive Plan (the “2019 Plan”) and approved an additional 700,000 shares, available for future grants (in addition to the 9,701,192 shares provided under the Prior Plan). In June 2021, stockholders approved an additional 450,000 shares for future grants. The 2019 Plan provides for the grant of incentive stock options, non-statutory stock options, RSAs restricted stock units (“RSUs”), stock appreciation rights, performance stock units, performance shares, and other stock or cash awards.

The Company issued 4,085 PSUs to a non-employee director during the three months ended June 30, 2021. The Company’s Board of Directors granted its executive officers, senior management and certain employees 82,549 and 171,137 performance stock units (“PSUs”) during the three and six months ended June 30, 2021. The PSUs granted in the three and six months ended June 30, 2021 vest subject to continued service and the Company’s achievement of certain operational goals for the 2021 fiscal year related to product milestones, sales and commercial milestones and certain cost reduction targets.

The Company issued 29,361 RSUs to its non-employee directors during the three months ended June 30, 2021. The Company’s Board of Directors also granted its executive officers and senior management 73,186 and 129,783 RSUs and 103,466 and

172,139 non-qualified stock options (“NQs”) during the three and six months ended June 30, 2021, respectively. The RSUs and NQs vest over four years with one-fourth vesting on the first anniversary of the vesting commencement date of January 1, 2021 and 1/36th of the underlying shares vesting each month thereafter.

On September 30, 2019, the Company's Board awarded its new CEO, David H. Mowry, 67,897 shares, which were scheduled to vest over four years from 2019 through 2022 (the 2019 tranche is 15% of the award, or 10,185 PSUs; the 2020 tranche is 25% of the award, or 16,974 PSUs; the 2021 tranche is 30% of the award, or 20,369 PSUs; the 2022 tranche is 30% of the award, or 20,369 PSUs). These PSUs are subject to certain performance-based vesting criteria related to the achievement of financial metrics included in the Board approved annual budgets for the years 2019 through 2022. As of June 30, 2021, the 2019, 2020 and 2021 tranches met the criteria for measurement and recognition. 8,657 shares of the 2019 tranche vested during the three months ended March 31, 2020. The 2020 tranche did not vest in accordance with the initial terms, however, during the quarter ending June 30, 2021, the Company’s Board of Directors approved the vesting of Mr. Mowry’s 2020 PSU tranche. Upon this modification to the vesting terms of the 2020 PSU tranche, the Company recognized $0.5 million of stock-based compensation expense in the quarter ending June 30, 2021.

Under the 2019 Plan, the Company issued 92,103 and 214,797 shares of common stock during the three and six months ended June 30, 2021, in conjunction with stock options exercised and the vesting of RSUs and PSUs, net of shares withheld for employee taxes.

As of June 30, 2021, the unrecognized compensation cost, net of expected forfeitures, was $2.0 million for stock options, which will be recognized over an estimated weighted-average remaining amortization period of 3.6 years. The unrecognized compensation cost, net of expected forfeitures, for stock awards, including performance-based awards, was $16.1 million, which will be recognized over an estimated weighted-average remaining amortization period of 2.0 years. The actual expense recorded in the future may vary based on a number of factors, including, actual forfeitures experienced and the degree of achievement of the performance goals related to the PSUs granted.

Activity under the 2019 Plans is summarized as follows:


		Options Outstanding
	Shares Available for Grant	Number of Stock Options Outstanding	Weighted- Average Exercise Price		Weighted Average Remaining Term (in Years)	Aggregate Intrinsic Value (in Millions)
Balance, December 31, 2020	1,085,170	217,007	$	22.35	3.75	$	1.47
Additional shares reserved	450,000	—	$	—
Awards granted	(354,735)	—	$	—
Options granted	(172,139)	172,139	$	30.71
Options exercised	—	(53,598)	$	23.34
Stock awards canceled / forfeited / expired	212,571	—	$	—
Options canceled / forfeited / expired	16,224	(16,224)	$	33.27
Balance, June 30, 2021	1,237,091	319,324	$	26.14	5.13	$	7.34


	Stock Awards Outstanding
	Number of Awards Outstanding	Weighted Average Grant Date Fair Value per Share		Aggregate Intrinsic Value (in Millions)
Balance, December 31, 2020	779,757	$	23.96	$	18.80

Stock awards granted	354,735	$	31.48
Awards released	(161,199)	$	22.33
Stock awards canceled / forfeited / expired	(212,571)	$	28.00
Balance, June 30, 2021	760,722	$	26.68	$	7.34

Stock-based Compensation Expense

Stock-based compensation expense by department recognized during the three and six months ended June 30, 2021 and 2020 was as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Cost of revenue	$	434	$	743	$	578	$	1,033
Sales and marketing	522		1,251		1,243		1,970
Research and development	307		769		608		1,090
General and administrative	1,656		1,332		2,336		1,982
Total stock-based compensation expense	$	2,919	$	4,095	$	4,765	$	6,075

Net Income (Loss) Per Share

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Net Income (Loss) Per Share

On January 1, 2021, the Company adopted the accounting standard update to simplify the accounting for convertible debt instruments. The Company now uses the if converted method for its Convertible notes in calculating the diluted net income per share, and includes the effect of potential share settlement for the Convertible notes, if the effect is dilutive.

Basic earnings per share (“EPS”) is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method or the if-converted method. Dilutive potential common shares include outstanding stock options, stock awards, performance stock awards, and conversion shares under the Convertible notes. The diluted EPS is computed with the assumption that the Company will settle the convertible debt in shares, rather than cash.

As of June 30, 2021, the Company’s Convertible notes were potentially convertible into 4,167,232 shares of common stock. The Company used the if converted stock method to calculate the potential dilutive effect of the conversion spread on diluted net income per share, for the three and six months ended June 30, 2021.

The denominator for diluted net income per share does not include any effect from the capped call transactions the Company entered into concurrently with the issuance of the Convertible notes, as this effect would be anti-dilutive. In the event of conversion of a Convertible note, shares delivered to the Company under the capped call will offset the dilutive effect of the shares that the Company would issue under the Convertible notes.

For the three and six months ended June 30, 2020, basic loss per common share and diluted loss per common share are the same as inclusion of any potentially issuable shares would be anti-dilutive.

The following table sets forth the computation of basic and diluted net income (loss) and the weighted average number of

shares used in computing basic and diluted net income (loss) per share (in thousands, except per share data):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Numerator:
Net income (loss) used in calculating net income (loss) per share, basic	$	7,746	$	(11,394)	$	7,387	$	(23,808)
Interest expense on Convertible notes, net of tax	758		—		740		—
Amortization of debt issuance cost, net of tax	209		—		204		—
Net income used in calculating net income per share, diluted	$	8,713	$	(11,394)	$	8,331	$	(23,808)
Denominator:
Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic	17,862		17,055		17,815		15,744
Dilutive effect of incremental shares and share equivalents:
Convertible notes	4,167		—		2,625		—
Options	65		—		63		—
RSUs	259		—		270		—
PSUs	77		—		64		—
ESPP	23		—		18		—
Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted	22,453		17,055		20,855		15,744
Net income (loss) per share:
Net income (loss) per share, basic	$	0.43	$	(0.67)	$	0.41	$	(1.51)
Net income (loss) per share, diluted	$	0.39	$	(0.67)	$	0.40	$	(1.51)

The following numbers of shares outstanding, prior to the application of the if converted stock method, were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have had an anti-dilutive effect (in thousands):


	Three Months Ended June 30,		Six Months Ended June 30,
	2021	2020	2021	2020
Capped call (1)	4,167	—	4,167	—
Options to purchase common stock	189	231	143	253
Restricted stock units	11	803	2	736
Performance stock units	—	71	—	145
Employee stock purchase plan shares	—	58	—	58
Total	4,367	1,163	4,312	1,192

(1)The Company entered into capped call transactions with certain financial institutions, which are generally designated to reduce common stock dilution upon conversion of the Convertible notes. The capped call transactions are excluded from the computation of diluted net income (loss) per common share as their effect would be anti-dilutive.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three and six months ended June 30, 2021, the Company's income tax expense was $0.1 million and $0.4 million, respectively, compared to $0.5 million for both three and six months ended June 30, 2020. The Company's income tax expense for the three and six months ended June 30, 2021 is due primarily to income taxes in foreign jurisdictions. The PPP loan forgiveness recognized during the three months ended June 30, 2021 is excluded from taxable income under Section 1106(i) of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The Company continues to maintain a full valuation allowance on its U.S. deferred tax assets. On March 27, 2020, the U.S. federal government enacted the CARES Act, which changed several of the existing U.S. corporate income tax laws by, among other things, increasing the amount of deductible interest, allowing companies to carry back certain Net Operating Losses (“NOLs”) and increasing the amount of NOLs that corporations can use to offset income. The CARES Act did not have a material impact on the Company's income tax provision, deferred tax assets and liabilities, and related taxes payable. The Company is currently assessing the future implications of these provisions within the CARES Act on the Company's consolidated financial statements, but does not expect the impact to be material.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Leases

6 Months Ended

Jun. 30, 2021

Leases [Abstract]

Leases

The Company is a party to certain operating and finance leases for vehicles, office space and storage facilities. The Company’s operating leases consist of office space, as well as storage facilities and finance leases consist of automobiles. The Company’s leases generally have remaining terms of one to ten years, some of which include options to renew the leases for up to five years. The Company leases space for operations in the United States, Japan, Belgium, France and Spain. In addition to the above facility leases, the Company also routinely leases automobiles for certain sales and field service employees under finance leases.

The Company determines if a contract contains a lease at inception. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent the right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, the Company estimates the incremental secured borrowing rates corresponding to the maturities of the leases. The Company based the rate estimates on prevailing financial market conditions, credit analysis, and management judgment.

The Company recognizes expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce the Company’s right-of-use (“ROU”) asset related to the lease. These are amortized through the ROU asset as reductions of expense over the lease term.

Supplemental balance sheet information related to leases was as follows (in thousands):


Leases	Classification	June 30, 2021		December 31, 2020
Assets
Right-of-use assets	Operating lease assets	$	15,919	$	17,076
Finance lease	Property and equipment, net (1)	602		467
Total leased assets		$	16,521	$	17,543

(1) Finance lease assets included in Property and equipment, net, in the condensed consolidated balance sheets.


Liabilities		June 30, 2021		December 31, 2020
Operating lease liabilities
Operating lease liabilities, current	Operating lease liabilities	$	2,422	$	2,260
Operating lease liabilities, non-current	Operating lease liabilities, net of current portion	14,705		15,950
Total Operating lease liabilities		$	17,127	$	18,210

Finance lease liabilities
Finance lease liabilities, current	Accrued liabilities (1)	$	429	$	370
Finance lease liabilities, non-current	Other long-term liabilities	288		241
Total Finance lease liabilities		$	717	$	611

(1) Finance lease liabilities included in Accrued liabilities in the condensed consolidated balance sheets.

Lease costs during the three and six months ended June 30, 2021 and 2020 (in thousands):


		Three Months Ended June 30,				Six Months Ended June 30,
Lease costs		2021		2020		2021		2020
Finance lease cost	Amortization expense	$	110	$	277	$	237	$	425
Finance lease cost	Interest for finance lease	$	14	$	16	$	28	$	35
Operating lease cost	Operating lease expense	$	881	$	728	$	1,759	$	1,456

Cash paid for amounts included in the measurement of lease liabilities during the six months ended June 30, 2021 and 2020 was as follows (in thousands):


		Six Months Ended June 30,
Cash paid for amounts included in the measurement of lease liabilities		2021		2020
Operating cash flow	Finance lease	$	27	$	35
Financing cash flow	Finance lease	$	211	$	380
Operating cash flow	Operating lease	$	1,549	$	1,454

Facility leases

Maturities of facility leases were as follows as of June 30, 2021 (in thousands):


As of June 30, 2021	Amount
Remainder of 2021	$	1,551
2022	3,152
2023	3,188
2024	2,879
2025	2,875
2026 and thereafter	6,308
Total lease payments	19,953
Less: imputed interest	2,826
Present value of lease liabilities	$	17,127

Vehicle Leases

As of June 30, 2021, the Company was committed to minimum lease payments for vehicles leased under long-term non-cancelable finance leases as follows (in thousands):


As of June 30, 2021	Amount
Remainder of 2021	$	241
2022	379
2023	125
2024	28
Total lease payments	773
Less: imputed interest	56
Present value of lease liabilities	$	717

Weighted-average remaining lease term and discount rate, as of June 30, 2021, were as follows:


Lease Term and Discount Rate	June 30, 2021
Weighted-average remaining lease term (years)
Operating leases	6.3
Finance leases	1.7
Weighted-average discount rate
Operating leases	4.7	%
Finance leases	6.5	%

Lessor Information related to the Company’s system leasing

During fiscal year ended December 31, 2020, the Company entered into leasing transactions, in which the Company is the lessor, offered through the Company's membership program. The Company's leases for equipment rentals were all accounted for as operating leases during the second and third quarters of 2020.

During the fourth quarter ended December 31, 2020, certain of the membership program agreements were amended, granting the customers the exclusive right and option to purchase the leased system from the Company, at any time during the period of 12 months from signing the amended agreement. For contracts signed under the amended membership agreement, the Company classified and accounted for the arrangements as sales-type leases as of December 31, 2020, as the Company determined it is reasonably certain that the customer will exercise the purchase option.

For the sales-type leases, the net investment of the Company’s lease receivable is measured at the commencement date and is included in the condensed consolidated balance sheets as a component of other current assets and prepaid expenses. As of December 31, 2020, the Company recorded $0.7 million of revenue for the sales-type leases in the condensed consolidated statement of operations and the related lease receivable in other current assets of the condensed consolidated balance sheet. There was no revenue recognized from the sales-type lease arrangement for the three and six months ended June 30, 2021 and 2020, respectively. During the three and six months ended June 30, 2021, the Company received a full payment of $0.1 million and $0.2 million from a customer who exercised its purchase option. As of June 30, 2021, the lease receivable balance included in other current assets of the condensed consolidated balance sheet was $0.5 million

Equipment lease revenue for operating lease agreements is recognized over the life of the lease. The amount of operating lease income included in Product revenue in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2021 was zero and $0.1 million, respectively.

Leases

Supplemental balance sheet information related to leases was as follows (in thousands):


Leases	Classification	June 30, 2021		December 31, 2020
Assets
Right-of-use assets	Operating lease assets	$	15,919	$	17,076
Finance lease	Property and equipment, net (1)	602		467
Total leased assets		$	16,521	$	17,543

(1) Finance lease assets included in Property and equipment, net, in the condensed consolidated balance sheets.


Liabilities		June 30, 2021		December 31, 2020
Operating lease liabilities
Operating lease liabilities, current	Operating lease liabilities	$	2,422	$	2,260
Operating lease liabilities, non-current	Operating lease liabilities, net of current portion	14,705		15,950
Total Operating lease liabilities		$	17,127	$	18,210

Finance lease liabilities
Finance lease liabilities, current	Accrued liabilities (1)	$	429	$	370
Finance lease liabilities, non-current	Other long-term liabilities	288		241
Total Finance lease liabilities		$	717	$	611

(1) Finance lease liabilities included in Accrued liabilities in the condensed consolidated balance sheets.

Lease costs during the three and six months ended June 30, 2021 and 2020 (in thousands):


		Three Months Ended June 30,				Six Months Ended June 30,
Lease costs		2021		2020		2021		2020
Finance lease cost	Amortization expense	$	110	$	277	$	237	$	425
Finance lease cost	Interest for finance lease	$	14	$	16	$	28	$	35
Operating lease cost	Operating lease expense	$	881	$	728	$	1,759	$	1,456

Cash paid for amounts included in the measurement of lease liabilities during the six months ended June 30, 2021 and 2020 was as follows (in thousands):


		Six Months Ended June 30,
Cash paid for amounts included in the measurement of lease liabilities		2021		2020
Operating cash flow	Finance lease	$	27	$	35
Financing cash flow	Finance lease	$	211	$	380
Operating cash flow	Operating lease	$	1,549	$	1,454

Facility leases

Maturities of facility leases were as follows as of June 30, 2021 (in thousands):


As of June 30, 2021	Amount
Remainder of 2021	$	1,551
2022	3,152
2023	3,188
2024	2,879
2025	2,875
2026 and thereafter	6,308
Total lease payments	19,953
Less: imputed interest	2,826
Present value of lease liabilities	$	17,127

Vehicle Leases

As of June 30, 2021, the Company was committed to minimum lease payments for vehicles leased under long-term non-cancelable finance leases as follows (in thousands):


As of June 30, 2021	Amount
Remainder of 2021	$	241
2022	379
2023	125
2024	28
Total lease payments	773
Less: imputed interest	56
Present value of lease liabilities	$	717

Weighted-average remaining lease term and discount rate, as of June 30, 2021, were as follows:


Lease Term and Discount Rate	June 30, 2021
Weighted-average remaining lease term (years)
Operating leases	6.3
Finance leases	1.7
Weighted-average discount rate
Operating leases	4.7	%
Finance leases	6.5	%

Lessor Information related to the Company’s system leasing

Leases

Supplemental balance sheet information related to leases was as follows (in thousands):


Leases	Classification	June 30, 2021		December 31, 2020
Assets
Right-of-use assets	Operating lease assets	$	15,919	$	17,076
Finance lease	Property and equipment, net (1)	602		467
Total leased assets		$	16,521	$	17,543

(1) Finance lease assets included in Property and equipment, net, in the condensed consolidated balance sheets.


Liabilities		June 30, 2021		December 31, 2020
Operating lease liabilities
Operating lease liabilities, current	Operating lease liabilities	$	2,422	$	2,260
Operating lease liabilities, non-current	Operating lease liabilities, net of current portion	14,705		15,950
Total Operating lease liabilities		$	17,127	$	18,210

Finance lease liabilities
Finance lease liabilities, current	Accrued liabilities (1)	$	429	$	370
Finance lease liabilities, non-current	Other long-term liabilities	288		241
Total Finance lease liabilities		$	717	$	611

(1) Finance lease liabilities included in Accrued liabilities in the condensed consolidated balance sheets.

Lease costs during the three and six months ended June 30, 2021 and 2020 (in thousands):


		Three Months Ended June 30,				Six Months Ended June 30,
Lease costs		2021		2020		2021		2020
Finance lease cost	Amortization expense	$	110	$	277	$	237	$	425
Finance lease cost	Interest for finance lease	$	14	$	16	$	28	$	35
Operating lease cost	Operating lease expense	$	881	$	728	$	1,759	$	1,456

Cash paid for amounts included in the measurement of lease liabilities during the six months ended June 30, 2021 and 2020 was as follows (in thousands):


		Six Months Ended June 30,
Cash paid for amounts included in the measurement of lease liabilities		2021		2020
Operating cash flow	Finance lease	$	27	$	35
Financing cash flow	Finance lease	$	211	$	380
Operating cash flow	Operating lease	$	1,549	$	1,454

Facility leases

Maturities of facility leases were as follows as of June 30, 2021 (in thousands):


As of June 30, 2021	Amount
Remainder of 2021	$	1,551
2022	3,152
2023	3,188
2024	2,879
2025	2,875
2026 and thereafter	6,308
Total lease payments	19,953
Less: imputed interest	2,826
Present value of lease liabilities	$	17,127

Vehicle Leases

As of June 30, 2021, the Company was committed to minimum lease payments for vehicles leased under long-term non-cancelable finance leases as follows (in thousands):


As of June 30, 2021	Amount
Remainder of 2021	$	241
2022	379
2023	125
2024	28
Total lease payments	773
Less: imputed interest	56
Present value of lease liabilities	$	717

Weighted-average remaining lease term and discount rate, as of June 30, 2021, were as follows:


Lease Term and Discount Rate	June 30, 2021
Weighted-average remaining lease term (years)
Operating leases	6.3
Finance leases	1.7
Weighted-average discount rate
Operating leases	4.7	%
Finance leases	6.5	%

Lessor Information related to the Company’s system leasing

Contingencies	6 Months Ended
Contingencies	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is named from time to time as a party to other legal proceedings, product liability, commercial disputes, employee disputes, and contractual lawsuits in the normal course of business. A liability and related charge are recorded to earnings in the Company’s consolidated financial statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no amount within the range is a better estimate than any other. If a material loss is reasonably possible, but not probable and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. The Company expenses legal fees as incurred. InMode Ltd. filed a complaint with the United States International Trade Commission alleging that Ilooda, Co., Ltd’s Secret RF fractional radiofrequency microneedling system, distributed in the United States by the Company, infringes U.S. Patent No. 10,799,285 ("285 patent"). The Company intends to vigorously defend against this lawsuit and, based on a preliminary investigation, believes that the Company has a strong defense and that the patent claim at issue is likely invalid in view of prior art. Based on the current information available to the Company, it believes that any possible loss will not be material. If, following a successful third-party action for infringement, the Company cannot obtain a license for the Company’s products, it may have to stop selling the applicable products. As of June 30, 2021 and December 31, 2020, the Company had accrued $0.9 million and $0.4 million, respectively, related to various pending commercial and product liability lawsuits. The Company does not believe that a material loss in excess of accrued amounts is reasonably likely.

Debt

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Debt

Convertible notes, net of unamortized debt issuance costs

In March 2021, the Company issued $138.3 million aggregate principal amount of convertible senior notes due on March 15, 2026 in a private placement offering. The Convertible notes bear interest at a rate of 2.25% per year payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2021. Upon conversion, the Convertible notes will be convertible into cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. The Convertible notes are presented as Convertible notes, net of unamortized debt issuance costs, on the condensed consolidated balance sheet. Proceeds from the offering were $133.6 million, net of issuance costs, including initial purchasers fees.

Initially, each $1,000 principal amount of Notes was convertible into 30.1427 shares of the Company’s common stock at a conversion price of $33.18 per share. The conversion rate for the Convertible notes is subject to adjustment for certain events as set forth in the Indenture governing the Convertible notes. The Convertible notes will mature on March 15, 2026, unless earlier converted, redeemed, or repurchased in accordance with the terms of the Convertible notes. No sinking fund is provided for the Notes. As of June 30, 2021, the net carrying amount of the Company’s Convertible notes was 133.9 million and the unamortized debt issuance costs were $4.4 million.

Holders may convert their Notes at their option prior to the close of business on the business day immediately preceding December 15, 2025, in multiples of $1,000 principal amount, only under the following circumstances:

•During any fiscal quarter commencing after the fiscal quarter ending on June 30, 2021 (and only during such fiscal quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on and including, the last trading day of the immediately preceding fiscal quarter, is greater than or equal to 130% of the conversion price for the Convertible notes on each applicable trading day;

•During the five-business day period after any five consecutive trading day period (the “measurement period”) in which the “trading price” per $1,000 principal amount of Convertible notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such trading day;

•The Company calls such Convertible notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or

•Upon the occurrence of specified corporate events.

On or after December 15, 2025, and until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances.

The circumstances described in the first bullet of the paragraph above were met during the second quarter of 2021 as the Company's stock traded at a price in excess of the conversion price, and as a result, the Notes are convertible at the option of the holder from July 1, 2021 until September 30, 2021. Upon any conversion of the Convertible notes, the Company would be required to pay or deliver, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at the Company’s election with respect to such conversion. To the extent there are any conversions during the period from July 1, 2021 until September 30, 2021, the Company intends to settle such conversions in shares of common stock, therefore, as of June 30, 2021, the Convertible notes have been included as Long-term debt on its condensed consolidated balance sheet.

The Company may not redeem the Convertible notes prior to March 20, 2024. On or after March 20, 2024, the Company may redeem for cash all or any portion of the Notes, at the Company’s option, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem fewer than all of the outstanding Notes, at least $50.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the relevant redemption notice date.

If a fundamental change occurs, note holders have the option to require the Company to repurchase any portion or all of their Convertible notes in $1,000 principal increments for cash. The price for such repurchase is calculated as 100% of the principal amounts of Notes, plus accrued and unpaid interest to the day immediately preceding the Fundamental Change repurchase date.

Additionally, holders of the Notes who convert in connection with a fundamental change are, under certain circumstances, entitled to an increase in conversion rate.

The Convertible notes are general senior unsecured obligations that rank senior to any of the Company’s indebtedness that is explicitly subordinated to the Notes. The Notes have equal rank in right of payment with all existing and future unsecured indebtedness that is not subordinated to the Notes. The Notes will be junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness. The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company.

The estimated fair value of the Convertible notes was approximately $226.4 million as of June 30, 2021, which the Company determined through consideration of market prices. The fair value measurement is classified as Level 2, as defined in Note 3.

The following table presents outstanding principal amount and carrying value of the Convertible notes (in thousands):


	June 30, 2021		December 31, 2020
Outstanding principal amount	$	138,250	$	—
Unamortized debt issuance costs	(4,450)		—
Carrying Value	$	133,800	$	—

In connection with issuance of the Convertible notes, the Company entered into capped call transactions with certain option counterparties. The capped call transactions are generally intended to reduce the potential dilution of the Company's common stock upon any conversion or settlement of the Notes or to offset any cash payment the Company is required to make in excess of the principal amount upon conversion of the Notes, as the case may be, with such reduction or offset subject to a cap based on the cap price. If the market price per share of the Company’s common stock exceeds the cap price of the capped calls transaction, then the Company’s stock would experience some dilution and/or the capped call would not fully offset the potential cash payments, in each case to the extent the then-market price per share of its common stock exceeds the cap price. Under the capped call transactions, the Company purchased from the option counterparties capped call options that in the aggregate relate to the total number of shares of the Company's common stock underlying the Convertible notes, with a strike price equal to the conversion price of the Convertible notes and with an initial cap price equal to $45.5350, which represents a 75% premium over the last reported sale price of the Company's common stock of $26.02 per share on March 4, 2021, with certain adjustments to the settlement terms that reflect standard anti-dilution provisions. The capped call transactions expire over 40 consecutive scheduled trading days ended on March 12, 2026. The capped calls were purchased for $16.1 million. The Company evaluated the capped call transaction under authoritative accounting guidance and determined that it should be accounted for as a separate transaction and classified as a net reduction to Additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded.

The Company early adopted ASU 2020-6, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40). In accordance with Subtopic 470-20 and 815-40, as revised by ASU 2020-6, the Company records the Convertible notes in long-term debt with no separation between the Notes and the conversion option. Each reporting period, the Company will determine whether any criteria is met for the note holders to have the option to redeem the Notes early, which could result in a change in the classification of the Notes to current liabilities.

Debt Issuance Cost

The issuance costs related to the Convertible notes are presented in the condensed consolidated balance sheet as a direct deduction from the carrying amount of the Convertible notes. During the six months ended June 30, 2021, the Company incurred direct costs associated with the issuance of Convertible notes of $4.7 million.

The issuance costs are amortized using an effective interest method basis over the term of the Convertible notes and accordingly the Company recorded approximately $0.2 million and $0.3 million of amortization of debt issuance costs during the three and six months ended June 30, 2021.

The effective interest rate on the Convertible notes is 2.97%. Interest expense for the three and six months ended June 30, 2021 totaled approximately $1.0 million and $1.2 million, respectively, of which $0.8 million and $1.0 million, respectively, relate to accruing the semiannual interest payment with the remaining balance relating to the amortization of debt issuance costs.

Loan and Security Agreement

On May 30, 2018, the Company and Wells Fargo Bank, N.A. (“Wells Fargo”) entered into a Loan and Security Agreement (the “Wells Fargo Revolving Line of Credit”) in the original principal amount of $25.0 million.

On July 9, 2020, the Company terminated its undrawn revolving line of credit with Wells Fargo and subsequently entered into a Loan and Security Agreement with Silicon Valley Bank for a four-year secured revolving loan facility (“SVB Revolving Line of Credit”) in an aggregate principal amount of up to $30.0 million. The SVB Revolving Line of Credit matures on July 9, 2024.

In order to draw on the full amount of the SVB Revolving Line of Credit, the Company must satisfy certain liquidity ratios. If the Company is unable to meet these liquidity ratios, then availability under the revolving line is calculated as 80% of the Company’s qualifying accounts receivable. The proceeds of the revolving loans may be used for general corporate purposes. The Company’s obligations under the Loan and Security Agreement with Silicon Valley Bank are secured by substantially all of the assets of the Company. Interest on principal amount outstanding under the revolving line shall accrue at a floating per annum rate equal to the greater of either 1.75% above the Prime Rate or five percent (5.0%). The Company paid a non-refundable revolving line commitment fee of $0.3 million, on the effective date of the Loan and Security Agreement with Silicon Valley Bank of July 9, 2020, and the Company is required to pay an anniversary fee of $0.3 million on each twelve-month anniversary of the effective date of the Loan and Security Agreement.

The Loan and Security Agreement with Silicon Valley Bank contains customary affirmative covenants, such as financial statement reporting requirements and delivery of borrowing base certificates, as well as customary covenants that restrict the Company’s ability to, among other things, incur additional indebtedness, sell certain assets, guarantee obligations of third parties, declare dividends, or make certain distributions, and undergo a merger or consolidation or certain other transactions. The Loan and Security Agreement also contains certain financial covenants, including maintaining a quarterly minimum revenue of $90.0 million, determined in accordance with GAAP on a trailing twelve-month basis.

On March 4, 2021, the Loan and Security Agreement dated July 9, 2020 was amended to (i) permit the Company to issue the Convertible notes and perform its obligations in connection therewith, and (ii) permit the Capped Call transactions.

As of June 30, 2021, the Company had not drawn on the SVB Revolving Line of Credit and the Company is in compliance with all financial covenants of the SVB Revolving Line of Credit.

The Paycheck Protection Program (PPP) Loan

On April 22, 2020, the Company received loan proceeds of $7.1 million pursuant to the Paycheck Protection Program (the “PPP”) under the CARES Act. The loan, which is in the form of a promissory note dated April 21, 2020, between the Company and Silicon Valley Bank as the lender, matures on April 21, 2022 and bears interest at a fixed rate of 1.00% per annum, payable monthly commencing September 2021. There is no prepayment penalty. Under the terms of the PPP, all or a portion of the principal may be forgiven if the loan proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs, benefits, rent, and utilities.

The PPP loan and related accrued interest were forgiven under the provisions of the CARES Act, and the $7.2 million gain on forgiveness of PPP loan was recorded as Gain on extinguishment of PPP loan in the condensed consolidated statement of operations for the three and six months ended June 30, 2021.

Segment Reporting

6 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Segment Reporting

Segment reportingSegment reporting is based on the “management approach,” following the method that management organizes the Company’s reportable segments for which separate financial information is made available to, and evaluated regularly by, the chief operating decision maker in allocating resources and in assessing performance. The Company’s chief operating decision makers ("CODM") are its Chief Executive Officer ("CEO") and Chief Financial Officer (“CFO”), who make decisions on allocating resources and in assessing performance. The CEO and CFO review the Company's consolidated results as one operating segment. In making operating decisions, the CODM primarily considers consolidated financial information, accompanied by disaggregated information about revenues by geography and product. All of the Company’s principal operations and decision-making functions are located in the U.S. The Company’s CODM view its operations, manages its business, and uses one measurement of profitability for the one operating segment - which sells aesthetic medical equipment and services, and distributes skincare products, to qualified medical practitioners. Substantially all of the Company’s long-lived assets are located in the U.S.

The following table presents a summary of revenue by geography for the three and six months June 30, 2021 and 2020 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Revenue mix by geography:
United States	$	22,972	$	10,915	$	41,816	$	24,699
Japan	17,421		8,517		33,976		15,679
Asia, excluding Japan	3,676		1,846		6,079		5,075
Europe	4,628		1,325		9,052		4,141
Rest of the World, other than United States, Asia and Europe	9,892		3,766		17,334		9,014
Total consolidated revenue	$	58,589	$	26,369	$	108,257	$	58,608
Revenue mix by product category:
Products	$	35,567	$	15,541	$	63,887	$	36,500
Consumables	4,433		1,426		7,358		3,959
Skincare	11,812		4,778		24,118		7,677
Total product revenue	51,812		21,745		95,363		48,136
Service	6,777		4,624		12,894		10,472
Total consolidated revenue	$	58,589	$	26,369	$	108,257	$	58,608

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Operations and Principles of Consolidation	Description of Operations and Principles of Consolidation Cutera, Inc. (“Cutera” or the “Company”) provides energy-based aesthetic systems for practitioners worldwide. The Company develops, manufactures, distributes, and markets energy-based product platforms for use by physicians and other qualified practitioners, enabling them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following system platforms: enlighten, excel, Secret PRO, Juliet, Secret RF, truSculpt and xeo. Several of the Company’s systems offer multiple hand pieces and applications, providing customers the flexibility to upgrade their systems. The sales of (i) systems, system upgrades, and hand pieces (collectively “Systems” revenue); (ii) replacement hand pieces, Titan, truSculpt 3D,truSculpt iD and truSculpt flex cycle refills, as well as single use disposable tips applicable to Secret PRO, Juliet and Secret RF (“Consumables” revenue); (iii) the distribution of third party manufactured skincare products (“Skincare” revenue); and (iv) the leasing of equipment through a membership program; are collectively classified as “Products” revenue. In addition to Products revenue, the Company generates revenue from the sale of post-warranty service contracts, parts, detachable hand piece replacements (except for Titan, truSculpt 3D, truSculpt iD and truSculpt flex) and service labor for the repair and maintenance of products that are out of warranty, all of which are collectively classified as “Service” revenue. The Company’s corporate headquarters and U.S. operations are located in Brisbane, California, where the Company conducts manufacturing, warehousing, research and development, regulatory, sales and marketing, service, and administrative activities. The Company also maintains regional distribution centers (“RDCs”) in select locations across the U.S. These RDCs serve as forward warehousing for systems and service parts in various geographies. The Company markets, sells and services its products through its sales and service employees in North America (including Canada), Australia, Austria, Belgium, France, Germany, Hong Kong, Japan, Spain, Switzerland, and the United Kingdom. Sales and services outside of these direct markets are made through a worldwide distributor network in over 42 countries. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries.
Basis of Presentation	Basis of Presentation In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements included in this report reflect all adjustments necessary for a fair statement of its condensed consolidated statements of financial position as of June 30, 2021 and December 31, 2020, and its condensed consolidated statements of results of operations, comprehensive income (loss), changes in equity, and cash flows for the three and six months ended June 30, 2021, and 2020. The December 31, 2020 condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The results for interim periods are not necessarily indicative of results for the entire year or any other interim period. Presentation of certain prior year balances have been updated to conform with current year presentation. All significant intercompany accounts and transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s previously filed audited financial statements and the related notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2021.
Risks and Uncertainties	Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, stability of global financial markets, cybersecurity breaches and other disruptions that could compromise the Company’s information or results, business disruptions that are caused by natural disasters or pandemic events, management of international activities, competition from substitute products and larger companies, ability to obtain and maintain regulatory approvals, government regulations and oversight, patent and other types of litigation, ability to protect proprietary technology from counterfeit versions of the Company's products, strategic relationships and dependence on key individuals. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The COVID-19 outbreak has negatively affected the United States and global economies. Though the economy is gradually recovering as of the second quarter of 2021, the timing and extent of a full global economic recovery is still uncertain. The spread of the coronavirus and the Delta variant in particular, has impacted the global economy broadly in 2020, including restrictions on travel, shifting work forces to work remotely and quarantine policies put into place by businesses and governments, had a material economic effect on the Company’s business during the year ended December 31, 2020 and in the six months ended June 30, 2021. Healthcare facilities in many countries effectively banned elective procedures and this had a significant impact on the Company. Many of the Company’s products are used in aesthetic elective procedures and as such, the bans on elective procedures substantially reduced the Company’s sales and marketing efforts in the early months of the pandemic and led the Company to implement cost control measures. Although the Company’s revenues and profits have improved compared to the first half of fiscal 2020 and the overall economic outlook has also improved in 2021, the COVID-19 outbreak continues to be fluid especially in light of the Delta variant, and the long-term impact on the Company's business due to COVID-19 is still uncertain. The Company cannot presently predict the scope and severity of any impacts in future periods from business shutdowns or disruptions due to the COVID-19 pandemic, but the impact on economic activity including the possibility of recession or financial market instability could have a material adverse effect on the Company’s business, revenue, operating results, cash flows and financial condition. The Company continues to assess whether any impairment of its goodwill or its long-lived assets has occurred and has determined that no charges, other than an impairment loss of $0.2 million on capitalized implementation costs of cloud-based customer relationship management (“CRM”) software occurred were necessary during the six months ended June 30, 2021. The Company will continue to monitor future conditions important to its assessment of potential impairment of its long-lived assets and goodwill, including the impacts of the COVID–19 pandemic and other ongoing impacts which are subject to uncertainty. The Company has experienced a significant increase in sales of skincare products under the exclusive distribution agreement with ZO Skin Health, Inc. (“ZO”), which allows the Company to sell ZO’s skincare products in Japan. The reason for the increase in skincare products sales may have been the result of changes in customers’ spending habits as customers purchased more aesthetic treatments that were able to be applied at home, due to limitations on in-person aesthetic procedures, social distancing and mask wearing requirements due to the COVID-19 pandemic. Future growth in sales of skincare products depends on customers’ spending habits, which may revert to original spending habits after the COVID-19 pandemic. Such changes may have a material adverse effect on the Company’s revenue, operating results, and cash flows.
Accounting Policies	Accounting Policies These unaudited condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC applicable to interim financial statements. While these statements reflect all normal recurring adjustments that are, in the opinion of management, necessary for fair presentation of the results of the interim period, they do not include all of the information and footnotes required by GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the financial statement disclosures in its annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 23, 2021. The Company uses the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the notes to condensed consolidated financial statements refer to the Company’s continuing operations. Note 13 provides information about the Company’s adoption of the new accounting standard for debt with conversion and other options, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. The Company issued $138.3 million of convertible senior notes ("Notes" or "Convertible notes") in a private placement offering on March 5, 2021. The Convertible notes bear interest at a rate of 2.25% per year. In accordance with Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-6, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), the Company recorded the Convertible notes as long-term debt with no separation between the Convertible notes and the conversion option. Each reporting period, the Company will determine whether any criteria is met for the note holders to have the option to redeem the Convertible notes early, which will result in a change in the classification of the Convertible notes to current liabilities. The circumstances described in the paragraph above were met during the second quarter of 2021 as the Company's stock traded at a price in excess of the conversion price, and as a result, the Notes are convertible at the option of the holder from July 1, 2021 until September 30, 2021. Upon any conversion of the Convertible notes, the Company would be required to pay or deliver, as the case may be, cash, shares of its common stock, or a combination of cash and shares of its common stock, at the Company’s election. To the extent there are any conversions during the period from July 1, 2021 until September 30, 2021, the Company intends to settle such conversions by issuing shares of common stock; therefore, as of June 30, 2021, the Convertible notes have been included as long term liability on the condensed consolidated balance sheet. The costs associated with issuance of the Convertible notes, including underwriters’ fees, are presented in the condensed consolidated balance sheet as a direct deduction from the carrying amount of the Convertible notes. The debt issuance costs are being amortized over the life of the Convertible notes as additional non-cash interest expense. In connection with issuance of the Convertible notes, the Company entered into capped call transactions with certain option counterparties. The capped call transactions are generally designated to reduce the potential dilution of the Company's common stock upon any conversion of the Notes. The capped calls were purchased for $16.1 million and recorded as a reduction to additional paid in capital in the condensed consolidated balance sheet as of June 30, 2021. The Company capitalized cloud computing systems implementation costs of $0.6 million during the three months ending June 30, 2021. These costs relate to an on-going implementation of a new Enterprise Resource Planning system and are included in Other long-term assets and Other current assets and prepaid expenses on the condensed consolidated balance sheet.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates. On an ongoing basis, management evaluates its estimates, including those related to warranty obligations, sales commission, allowance for credit losses, sales allowances, valuation of inventories, fair value of goodwill, useful lives of property and equipment, impairment testing for long-lived-assets, implicit and incremental borrowing rates related to the Company’s leases, variables used in calculating the fair value of the Company's equity awards, expected achievement of performance based vesting criteria, management performance bonuses, assumptions used in operating and sales-type lease classification, the standalone selling price of the Company's products and services, the period of benefit used to capitalize and amortize contract acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, residual value of leased equipment, lease term and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Recently Adopted Accounting Pronoucements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes, to remove certain exceptions and improve consistency of application, including, among other things, requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company adopted this guidance in the three and six months ended June 30, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial position and results of operations. In August 2020, the FASB issued ASU No. 2020-6, Debt – Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815), to simplify the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the amendment, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the computation of diluted earnings per share. The Company early adopted the guidance on a prospective basis effective January 1, 2021. See Note 13 – Debt.

Cash, Cash Equivalents (Tables)

6 Months Ended

Jun. 30, 2021

Cash and Cash Equivalents [Abstract]

Summary of Cash and Cash Equivalents

The following table summarizes the Company's cash and cash equivalents (in thousands):


(Dollars in thousands)	June 30, 2021		December 31, 2020
Cash and cash equivalents	$	169,200	$	47,047

Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Inventories

As of June 30, 2021 and December 31, 2020, inventories consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Raw materials	$	15,862	$	14,874
Work in process	1,145		1,030
Finished goods	17,584		12,604
Total	$	34,591	$	28,508

Schedule of Accrued Liabilities

As of June 30, 2021 and December 31, 2020, accrued liabilities consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Accrued payroll and related expenses	$	16,427	$	12,197
Sales and marketing accruals	3,124		2,352
Accrued inventory in transit	4,469		2,476
Product warranty	3,789		2,908
Accrued sales tax	5,439		5,343
Other accrued liabilities	8,095		5,803
Total	$	41,343	$	31,079

Warranty and Extended Service Contract (Tables)

6 Months Ended

Jun. 30, 2021

Product Warranties Disclosures [Abstract]

Product Warranty Liability Accrual

The following table provides the changes in the product warranty accrual for the three and six months ended June 30, 2021 and 2020 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020 (1)		2021		2020 (1)
Beginning Balance	$	3,351	$	3,398	$	2,908	$	4,401
Add: Accruals for warranties issued during the period	2,210		1,100		3,735		1,960
Less: Settlements made during the period	(1,772)		(1,343)		(2,854)		(3,206)
Ending Balance	$	3,789	$	3,155	$	3,789	$	3,155

Deferred Revenue (Tables)

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Summary of Deferred Service Contract Revenue

The following table provides changes in the deferred revenue balance for the three and six months ended June 30, 2021 and 2020 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Beginning balance	$	11,737	$	12,969	$	11,237	$	14,222
Add: Payments received	4,423		2,554		9,352		6,125
Less: Revenue	(1,834)		(1,107)		(2,279)		(1,699)
Less: Revenue included in the beginning balance and recognized as revenue in the current quarter	(2,923)		(2,637)		(6,907)		(6,869)
Ending balance	$	11,403	$	11,779	$	11,403	$	11,779

Stockholders' Equity and Stock-based Compensation Expense (Tables)

6 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Summary of Activity under the 2019 Plan

Activity under the 2019 Plans is summarized as follows:


		Options Outstanding
	Shares Available for Grant	Number of Stock Options Outstanding	Weighted- Average Exercise Price		Weighted Average Remaining Term (in Years)	Aggregate Intrinsic Value (in Millions)
Balance, December 31, 2020	1,085,170	217,007	$	22.35	3.75	$	1.47
Additional shares reserved	450,000	—	$	—
Awards granted	(354,735)	—	$	—
Options granted	(172,139)	172,139	$	30.71
Options exercised	—	(53,598)	$	23.34
Stock awards canceled / forfeited / expired	212,571	—	$	—
Options canceled / forfeited / expired	16,224	(16,224)	$	33.27
Balance, June 30, 2021	1,237,091	319,324	$	26.14	5.13	$	7.34


	Stock Awards Outstanding
	Number of Awards Outstanding	Weighted Average Grant Date Fair Value per Share		Aggregate Intrinsic Value (in Millions)
Balance, December 31, 2020	779,757	$	23.96	$	18.80

Stock awards granted	354,735	$	31.48
Awards released	(161,199)	$	22.33
Stock awards canceled / forfeited / expired	(212,571)	$	28.00
Balance, June 30, 2021	760,722	$	26.68	$	7.34

Summary of Stock-based Compensation Expense

Stock-based compensation expense by department recognized during the three and six months ended June 30, 2021 and 2020 was as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Cost of revenue	$	434	$	743	$	578	$	1,033
Sales and marketing	522		1,251		1,243		1,970
Research and development	307		769		608		1,090
General and administrative	1,656		1,332		2,336		1,982
Total stock-based compensation expense	$	2,919	$	4,095	$	4,765	$	6,075

Net Income (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Income (Loss)

The following table sets forth the computation of basic and diluted net income (loss) and the weighted average number of

shares used in computing basic and diluted net income (loss) per share (in thousands, except per share data):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Numerator:
Net income (loss) used in calculating net income (loss) per share, basic	$	7,746	$	(11,394)	$	7,387	$	(23,808)
Interest expense on Convertible notes, net of tax	758		—		740		—
Amortization of debt issuance cost, net of tax	209		—		204		—
Net income used in calculating net income per share, diluted	$	8,713	$	(11,394)	$	8,331	$	(23,808)
Denominator:
Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic	17,862		17,055		17,815		15,744
Dilutive effect of incremental shares and share equivalents:
Convertible notes	4,167		—		2,625		—
Options	65		—		63		—
RSUs	259		—		270		—
PSUs	77		—		64		—
ESPP	23		—		18		—
Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted	22,453		17,055		20,855		15,744
Net income (loss) per share:
Net income (loss) per share, basic	$	0.43	$	(0.67)	$	0.41	$	(1.51)
Net income (loss) per share, diluted	$	0.39	$	(0.67)	$	0.40	$	(1.51)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


	Three Months Ended June 30,		Six Months Ended June 30,
	2021	2020	2021	2020
Capped call (1)	4,167	—	4,167	—
Options to purchase common stock	189	231	143	253
Restricted stock units	11	803	2	736
Performance stock units	—	71	—	145
Employee stock purchase plan shares	—	58	—	58
Total	4,367	1,163	4,312	1,192

Leases (Tables)

6 Months Ended

Jun. 30, 2021

Leases [Abstract]

Supplemental Balance Sheet Information

Supplemental balance sheet information related to leases was as follows (in thousands):


Leases	Classification	June 30, 2021		December 31, 2020
Assets
Right-of-use assets	Operating lease assets	$	15,919	$	17,076
Finance lease	Property and equipment, net (1)	602		467
Total leased assets		$	16,521	$	17,543

(1) Finance lease assets included in Property and equipment, net, in the condensed consolidated balance sheets.


Liabilities		June 30, 2021		December 31, 2020
Operating lease liabilities
Operating lease liabilities, current	Operating lease liabilities	$	2,422	$	2,260
Operating lease liabilities, non-current	Operating lease liabilities, net of current portion	14,705		15,950
Total Operating lease liabilities		$	17,127	$	18,210

Finance lease liabilities
Finance lease liabilities, current	Accrued liabilities (1)	$	429	$	370
Finance lease liabilities, non-current	Other long-term liabilities	288		241
Total Finance lease liabilities		$	717	$	611

(1) Finance lease liabilities included in Accrued liabilities in the condensed consolidated balance sheets.

Weighted-average remaining lease term and discount rate, as of June 30, 2021, were as follows:


Lease Term and Discount Rate	June 30, 2021
Weighted-average remaining lease term (years)
Operating leases	6.3
Finance leases	1.7
Weighted-average discount rate
Operating leases	4.7	%
Finance leases	6.5	%

Summary of Lease Costs

Lease costs during the three and six months ended June 30, 2021 and 2020 (in thousands):


		Three Months Ended June 30,				Six Months Ended June 30,
Lease costs		2021		2020		2021		2020
Finance lease cost	Amortization expense	$	110	$	277	$	237	$	425
Finance lease cost	Interest for finance lease	$	14	$	16	$	28	$	35
Operating lease cost	Operating lease expense	$	881	$	728	$	1,759	$	1,456

Cash paid for amounts included in the measurement of lease liabilities during the six months ended June 30, 2021 and 2020 was as follows (in thousands):


		Six Months Ended June 30,
Cash paid for amounts included in the measurement of lease liabilities		2021		2020
Operating cash flow	Finance lease	$	27	$	35
Financing cash flow	Finance lease	$	211	$	380
Operating cash flow	Operating lease	$	1,549	$	1,454

Summary of Maturities of Facility Leases

Maturities of facility leases were as follows as of June 30, 2021 (in thousands):


As of June 30, 2021	Amount
Remainder of 2021	$	1,551
2022	3,152
2023	3,188
2024	2,879
2025	2,875
2026 and thereafter	6,308
Total lease payments	19,953
Less: imputed interest	2,826
Present value of lease liabilities	$	17,127

Summary of Minimum Finance Lease Payments

As of June 30, 2021, the Company was committed to minimum lease payments for vehicles leased under long-term non-cancelable finance leases as follows (in thousands):


As of June 30, 2021	Amount
Remainder of 2021	$	241
2022	379
2023	125
2024	28
Total lease payments	773
Less: imputed interest	56
Present value of lease liabilities	$	717

Debt (Tables)

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Summary of Convertible Notes

The following table presents outstanding principal amount and carrying value of the Convertible notes (in thousands):


	June 30, 2021		December 31, 2020
Outstanding principal amount	$	138,250	$	—
Unamortized debt issuance costs	(4,450)		—
Carrying Value	$	133,800	$	—

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Summary of Revenue by Geography

The following table presents a summary of revenue by geography for the three and six months June 30, 2021 and 2020 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Revenue mix by geography:
United States	$	22,972	$	10,915	$	41,816	$	24,699
Japan	17,421		8,517		33,976		15,679
Asia, excluding Japan	3,676		1,846		6,079		5,075
Europe	4,628		1,325		9,052		4,141
Rest of the World, other than United States, Asia and Europe	9,892		3,766		17,334		9,014
Total consolidated revenue	$	58,589	$	26,369	$	108,257	$	58,608
Revenue mix by product category:
Products	$	35,567	$	15,541	$	63,887	$	36,500
Consumables	4,433		1,426		7,358		3,959
Skincare	11,812		4,778		24,118		7,677
Total product revenue	51,812		21,745		95,363		48,136
Service	6,777		4,624		12,894		10,472
Total consolidated revenue	$	58,589	$	26,369	$	108,257	$	58,608

Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands		3 Months Ended	6 Months Ended
	Mar. 05, 2021 USD ($)	Jun. 30, 2021 USD ($) country	Jun. 30, 2021 USD ($) country	Jun. 30, 2020 USD ($)	Mar. 31, 2021
Product Information [Line Items]
Number of countries in which entity utilizes a distributor network \| country		42	42
Impairment loss			$ 200
Proceeds from issuance of Convertible notes			$ 138,250	$ 7,149
Capitalized cloud computing systems implementation costs		$ 600
Convertible Senior Notes Due 2026
Product Information [Line Items]
Capped call transactions costs	$ 16,100
Convertible Notes \| Convertible Senior Notes Due 2026
Product Information [Line Items]
Proceeds from issuance of Convertible notes	$ 138,300
Interest rate	2.25%				2.25%

Cash, Cash Equivalents - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 169,200	$ 47,047

Cash, Cash Equivalents - Narrative (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Marketable Securities	$ 0	$ 0

Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 15,862	$ 14,874
Work in process	1,145	1,030
Finished goods	17,584	12,604
Total	$ 34,591	$ 28,508

Balance Sheet Details - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related expenses	$ 16,427	$ 12,197
Sales and marketing accruals	3,124	2,352
Accrued inventory in transit	4,469	2,476
Product warranty	3,789	2,908
Accrued sales tax	5,439	5,343
Other accrued liabilities	8,095	5,803
Total	$ 41,343	$ 31,079

Balance Sheet Details - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2018	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Product Warranty Liability [Line Items]
Standard product warranty accrual	$ 3,789	$ 3,155		$ 3,789	$ 3,155	$ 3,351	$ 2,908	$ 3,398	$ 4,401
Extended product warranty accrual	600	1,700		600	1,700
Standard and extended product warranty, excess reserves	100			200
Product Remediation Liability
Product Warranty Liability [Line Items]
Product warranty accrual, Increase for warranties issued, total			$ 5,000
Standard product warranty accrual	300			300			300
Extended product warranty accrual	700			700			$ 1,200
Costs incurred related to product warranty and extended warranty liability	$ 100	$ 0		$ 500	$ 300

Warranty and Extended Service Contract - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2018
Product Warranties Disclosures [Abstract]
Extended service contracts charge	$ 100	$ 300	$ 100	$ 300	$ 3,200
Settlements	$ 1,772	$ 1,343	$ 2,854	$ 3,206

Warranty and Extended Service Contract - Summary of Warranties (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning Balance	$ 3,351	$ 3,398	$ 2,908	$ 4,401
Add: Accruals for warranties issued during the period	2,210	1,100	3,735	1,960
Less: Settlements made during the period	(1,772)	(1,343)	(2,854)	(3,206)
Ending Balance	3,789	3,155	3,789	3,155
Extended product warranty accrual	$ 600	$ 1,700	$ 600	$ 1,700

Deferred Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue balance, amount	$ 11.4		$ 11.4
Costs for Extended Service Contracts	$ 2.2	$ 2.3	$ 4.2	$ 3.5
Service
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Extended service contract, option one, term			1 year
Extended service contract, option two, term			2 years
Extended service contract, option three, term			3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue balance, percentage	84.00%		84.00%
Expected timing of satisfaction, period	12 months		12 months

Deferred Revenue - Summary of Deferred Service Contract Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Change in Contract with Customer, Liability [Roll Forward]
Beginning balance	$ 11,737	$ 12,969	$ 11,237	$ 14,222
Add: Payments received	4,423	2,554	9,352	6,125
Less: Revenue	(1,834)	(1,107)	(2,279)	(1,699)
Less: Revenue included in the beginning balance and recognized as revenue in the current quarter	(2,923)	(2,637)	(6,907)	(6,869)
Ending balance	$ 11,403	$ 11,779	$ 11,403	$ 11,779

Revenue - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Revenue - Narrative (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Typical payment receipt, period post shipment			30 days
Sales-type lease, revenue	$ 0	$ 0	$ 0	$ 0	$ 700,000
Training provided with sale of system, period			180 days
Contract with customer, liability	$ 11,403,000	11,779,000	$ 11,403,000	11,779,000	11,237,000	$ 11,737,000	$ 12,969,000	$ 14,222,000
Minimum
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost, Amortization Period	2 years		2 years
Maximum
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost, Amortization Period	3 years		3 years
Sales and marketing
Disaggregation of Revenue [Line Items]
Amortization expense	$ 500,000	$ 700,000	$ 1,000,000.0	$ 1,400,000
Other Assets
Disaggregation of Revenue [Line Items]
Capitalized contract costs	3,600,000		$ 3,600,000		3,400,000
Service
Disaggregation of Revenue [Line Items]
Extended service contract, option one, term			1 year
Extended service contract, option two, term			2 years
Extended service contract, option three, term			3 years
Customer Marketing Support
Disaggregation of Revenue [Line Items]
Term of contract			6 months
Loyalty
Disaggregation of Revenue [Line Items]
Contract with customer, liability	$ 600,000		$ 600,000		$ 300,000
Skincare \| Japan
Disaggregation of Revenue [Line Items]
Sale of third-party product, warranty period			90 days
Transferred over Time \| Service
Disaggregation of Revenue [Line Items]
Revenue from performance obligations transferred to customers, percent	12.00%	12.00%	18.00%	18.00%

Stockholders' Equity and Stock-based Compensation Expense - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended			6 Months Ended
	Sep. 30, 2019	Jun. 30, 2021	Jun. 30, 2019	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	May 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)							354,735
Options granted in period (in shares)							172,139
Total stock-based compensation expense				$ 2,919		$ 4,095	$ 4,765	$ 6,075
Stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)							354,735
Vested in period (in shares)							161,199
Unrecognized compensation cost		$ 16,100		$ 16,100			$ 16,100
Estimated weighted-average remaining amortization period							2 years
PSUs \| Non-Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)				4,085
PSUs \| Executive Officers, Senior Management, and Certain Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)				82,549			171,137
PSUs \| CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)	67,897
Vesting period	4 years
PSUs \| 2019 Tranche \| CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)	10,185
Award vesting rights (percentage)	15.00%
Vested in period (in shares)					8,657
PSUs \| 2020 Tranche \| CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)	16,974
Award vesting rights (percentage)	25.00%
Total stock-based compensation expense				$ 500
PSUs \| 2021 Tranche \| CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)	20,369
Award vesting rights (percentage)	30.00%
PSUs \| 2022 Tranche \| CEO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)	20,369
Award vesting rights (percentage)	30.00%
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							4 years
Award vesting rights (percentage)							25.00%
Award vesting rights, monthly after first year (percentage)							2.78%
RSUs \| Non-Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)				29,361
RSUs \| Executive Officers And Senior Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)				73,186			129,783
Non-qualified Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							4 years
Award vesting rights (percentage)							25.00%
Award vesting rights, monthly after first year (percentage)							2.78%
Non-qualified Stock Options \| Executive Officers And Senior Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period (in shares)				103,466			172,139
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost		$ 2,000		$ 2,000			$ 2,000
Estimated weighted-average remaining amortization period							3 years 7 months 6 days
2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized (in shares)		450,000	700,000
Issuance of common stock (in shares)				92,103			214,797
Prior Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized (in shares)									9,701,192

Stockholders' Equity and Stock-based Compensation Expense - Activity Of Options Outstanding Under the 2019 Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Shares Available for Grant
Beginning balance (in shares)	1,085,170
Additional shares reserved (in shares)	450,000
Awards granted (in shares)	(354,735)
Options granted (in shares)	(172,139)
Options exercised (in shares)	0
Stock awards canceled (in shares)	212,571
Options canceled (in shares)	16,224
Ending balance (in shares)	1,237,091	1,085,170
Number of Stock Options Outstanding
Beginning balance (in shares)	217,007
Options granted (in shares)	172,139
Options exercised (in shares)	(53,598)
Options canceled (in shares)	(16,224)
Ending balance (in shares)	319,324	217,007
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 22.35
Granted (in dollars per share)	30.71
Options exercised (in dollars per share)	23.34
Options canceled (in dollars per share)	33.27
Ending balance (in dollars per share)	$ 26.14	$ 22.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Term (in Years)	5 years 1 month 17 days	3 years 9 months
Aggregate Intrinsic Value, beginning balance	$ 1,470
Aggregate Intrinsic Value, ending balance	$ 7,340	$ 1,470

Stockholders' Equity and Stock-based Compensation Expense - Activity of Stock Awards Outstanding Under the 2019 Plans (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($) $ / shares shares
Number of Awards Outstanding
Stock awards granted (in shares)	354,735
Stock awards canceled / forfeited / expired (in shares)	(212,571)
Stock awards
Number of Awards Outstanding
Beginning balance (in shares)	779,757
Stock awards granted (in shares)	354,735
Awards released (in shares)	(161,199)
Stock awards canceled / forfeited / expired (in shares)	(212,571)
Ending balance (in shares)	760,722
Weighted Average Grant Date Fair Value per Share
Beginning balance (in dollars per share) \| $ / shares	$ 23.96
Stock awards granted (in dollars per share) \| $ / shares	31.48
Awards released (in dollars per share) \| $ / shares	22.33
Stock awards canceled / forfeited / expired (in dollars per share) \| $ / shares	28.00
Ending balance (in dollars per share) \| $ / shares	$ 26.68
Aggregate Intrinsic Value (in Millions)
Beginning balance \| $	$ 18,800
Ending balance \| $	$ 7,340

Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense By Department (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,919	$ 4,095	$ 4,765	$ 6,075
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	434	743	578	1,033
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	522	1,251	1,243	1,970
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	307	769	608	1,090
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,656	$ 1,332	$ 2,336	$ 1,982

Net Income (Loss) Per Share - Narrative (Details)	6 Months Ended
Net Income (Loss) Per Share - Narrative (Details)	Jun. 30, 2021 shares
Convertible Senior Notes Due 2026 \| Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt convertible to common shares (in shares)	4,167,232

Net Income (Loss) Per Share - Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net income (loss) used in calculating net income (loss) per share, basic	$ 7,746	$ (11,394)	$ 7,387	$ (23,808)
Interest expense on Convertible notes, net of tax	758	0	740	0
Amortization of debt issuance cost, net of tax	209	0	204	0
Net income used in calculating net income per share, diluted	$ 8,713	$ (11,394)	$ 8,331	$ (23,808)
Denominator:
Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic (in shares)	17,862	17,055	17,815	15,744
Dilutive effect of incremental shares and share equivalents:
Convertible notes (in shares)	4,167	0	2,625	0
Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted (in shares)	22,453	17,055	20,855	15,744
Net income (loss) per share:
Net income (loss) per share, basic (USD per share)	$ 0.43	$ (0.67)	$ 0.41	$ (1.51)
Net income (loss) per share, diluted (USD per share)	$ 0.39	$ (0.67)	$ 0.40	$ (1.51)
Options
Dilutive effect of incremental shares and share equivalents:
Dilutive effect of share-based payment arrangements (in shares)	65	0	63	0
RSUs
Dilutive effect of incremental shares and share equivalents:
Dilutive effect of share-based payment arrangements (in shares)	259	0	270	0
PSUs
Dilutive effect of incremental shares and share equivalents:
Dilutive effect of share-based payment arrangements (in shares)	77	0	64	0
ESPP
Dilutive effect of incremental shares and share equivalents:
Dilutive effect of share-based payment arrangements (in shares)	23	0	18	0

Net Income (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,367	1,163	4,312	1,192
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,167	0	4,167	0
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	189	231	143	253
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	11	803	2	736
Performance stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	71	0	145
Employee stock purchase plan shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	58	0	58

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income tax expense	$ 122	$ 466	$ 380	$ 543

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Leases - Narrative (Details) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
Leases - Narrative (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Operating leases renewal terms (up to)	5 years			5 years
Finance leases renewal terms (up to)	5 years			5 years
Lessor, Lease, Description [Line Items]
Customers' right to purchase leased system, term		12 months
Sales-type lease, revenue	$ 0		$ 0	$ 0	$ 0	$ 700,000
Proceeds from customer's exercise of purchase option	100,000			200,000
Revenue from equipment leases	$ 0			$ 100,000
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms of operating leases	1 year			1 year
Remaining lease terms of finance leases	1 year			1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms of operating leases	10 years			10 years
Other Current Assets
Lessor, Lease, Description [Line Items]
Sales-type lease receivable	$ 500,000	$ 700,000		$ 500,000		$ 700,000

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Assets
Right-of-use assets	$ 15,919	$ 17,076
Finance lease	602	467
Total leased assets	$ 16,521	$ 17,543
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property and equipment, net	Property and equipment, net
Operating lease liabilities
Operating lease liabilities, current	$ 2,422	$ 2,260
Operating lease liabilities, non-current	14,705	15,950
Total Operating lease liabilities	17,127	18,210
Finance lease liabilities
Finance lease liabilities, current	429	370
Finance lease liabilities, non-current	288	241
Total Finance lease liabilities	$ 717	$ 611
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued liabilities		Accrued liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities		Other long-term liabilities

Leases - Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Leases - Lease Costs (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Finance lease cost, Amortization expense	$ 110	$ 277	$ 237	$ 425
Finance lease cost, Interest for finance lease	14	16	28	35
Operating lease cost	$ 881	$ 728	$ 1,759	$ 1,456

Leases - Cash Paid for Amounts Included in the Measurement of Lease Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating cash flow, Finance lease	$ 27	$ 35
Financing cash flow, Finance lease	211	380
Operating cash flow, Operating lease	$ 1,549	$ 1,454

Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Remainder of 2021	$ 1,551
2022	3,152
2023	3,188
2024	2,879
2025	2,875
2026	6,308
Total lease payments	19,953
Less: imputed interest	2,826
Present value of lease liabilities	$ 17,127	$ 18,210

Leases - Maturities of Finance Leases Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Remainder of 2021	$ 241
2022	379
2023	125
2024	28
Total lease payments	773
Less: imputed interest	56
Present value of lease liabilities	$ 717	$ 611

Leases - Lease Information (Details)	Jun. 30, 2021
Weighted-average remaining lease term (years)
Operating leases	6 years 3 months 18 days
Finance leases	1 year 8 months 12 days
Weighted-average discount rate
Operating leases	4.70%
Finance leases	6.50%

Contingencies - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Pending Litigation
Loss Contingencies [Line Items]
Estimated Litigation Liability	$ 0.9	$ 0.4

Debt - Narrative (Details)			1 Months Ended	3 Months Ended		6 Months Ended
Debt - Narrative (Details)	Jul. 09, 2020 USD ($)	Apr. 22, 2020 USD ($)	Mar. 31, 2021 USD ($) day $ / shares $ / item	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Mar. 05, 2021	Mar. 04, 2021 $ / shares	May 30, 2018 USD ($)
Debt Instrument [Line Items]
Cap price (in USD per per share) \| $ / item			45.5350
Premium over stock price (percent)			75.00%
Stock price (in USD per share) \| $ / shares									$ 26.02
Capped-call transaction term, consecutive trading days \| day			40
Purchase of capped call			$ 16,100,000			$ 16,134,000	$ 0
Interest on Convertible notes				$ 778,000	$ 0	969,000	0
Gain on extinguishment of PPP loan				7,185,000	$ 0	7,185,000	$ 0
Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Convertible debt, conversion ratio			0.0301
Convertible Senior Notes Due 2026 \| Common Stock
Debt Instrument [Line Items]
Conversion price (in dollars per share) \| $ / shares			$ 33.18
Loan and Security Agreement \| Wells Fargo \| Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity										$ 25,000,000.0
Loan and Security Agreement \| Silicon Valley Bank \| Revolving Credit Facility
Debt Instrument [Line Items]
Interest rate	5.00%
Maximum borrowing capacity	$ 30,000,000.0
Debt instrument term	4 years
Qualifying accounts receivable	80.00%
Commitment fee amount	$ 300,000
Anniversary fee amount	300,000
Quarterly minimum revenue	$ 90,000,000.0
Loan and Security Agreement \| Silicon Valley Bank \| Revolving Credit Facility \| Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.75%
PPP Loan
Debt Instrument [Line Items]
Interest rate		1.00%
Loan proceeds		$ 7,100,000
Gain on extinguishment of PPP loan				7,200,000		7,200,000
Convertible Notes \| Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Notes issued			$ 138,300,000
Interest rate			2.25%					2.25%
Proceeds from Debt, Net of Issuance Costs			$ 133,600,000
Carrying amount of convertible debt				133,900,000		133,900,000
Unamortized debt issuance costs				4,400,000		4,400,000
Redemption threshold percentage of stock price trigger			130.00%
Redemption threshold trading days \| day			20
Redemption threshold consecutive trading days \| day			30
Redemption price, percentage			100.00%
Required outstanding amount not subject to redemption			$ 50,000,000.0
Debt issuance costs				4,700,000		4,700,000
Amortization of debt issuance cost, net of tax				$ 200,000		$ 300,000
Effective interest rate during period				2.97%		2.97%
Interest on Convertible notes				$ 1,000,000.0		$ 1,200,000
Interest expense, excluding amortization				800,000		1,000,000.0
Convertible Notes \| Convertible Senior Notes Due 2026 \| Occurrence of Fundamental Change
Debt Instrument [Line Items]
Redemption price, percentage			100.00%
Incremental repurchase amount			$ 1,000
Convertible Notes \| Convertible Senior Notes Due 2026 \| Level 2
Debt Instrument [Line Items]
Convertible debt at fair value				$ 226,400,000		$ 226,400,000
Convertible Notes \| Convertible Senior Notes Due 2026, First Conversion Trigger
Debt Instrument [Line Items]
Conversion threshold trading days \| day			20
Threshold Consecutive trading days \| day			30
Conversion threshold percentage of stock price trigger			130.00%
Convertible Notes \| Convertible Senior Notes Due 2026, Second Conversion Trigger
Debt Instrument [Line Items]
Conversion threshold trading days \| day			5
Threshold Consecutive trading days \| day			5
Conversion threshold percentage of stock price trigger			98.00%

Debt - Outstanding Debt and Carrying Value (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Unamortized debt issuance costs	$ (4,450)
Convertible Senior Notes Due 2026 \| Convertible Notes
Debt Instrument [Line Items]
Outstanding principal amount	138,250	$ 0
Unamortized debt issuance costs	(4,450)	0
Carrying Value	$ 133,800	$ 0

Segment Reporting - Narrative (Details)	6 Months Ended
Segment Reporting - Narrative (Details)	Jun. 30, 2021 segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Reporting - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Total net revenue	$ 58,589	$ 26,369	$ 108,257	$ 58,608
Total product revenue
Disaggregation of Revenue [Line Items]
Total net revenue	51,812	21,745	95,363	48,136
Products
Disaggregation of Revenue [Line Items]
Total net revenue	35,567	15,541	63,887	36,500
Consumables
Disaggregation of Revenue [Line Items]
Total net revenue	4,433	1,426	7,358	3,959
Skincare
Disaggregation of Revenue [Line Items]
Total net revenue	11,812	4,778	24,118	7,677
Service
Disaggregation of Revenue [Line Items]
Total net revenue	6,777	4,624	12,894	10,472
United States
Disaggregation of Revenue [Line Items]
Total net revenue	22,972	10,915	41,816	24,699
Japan
Disaggregation of Revenue [Line Items]
Total net revenue	17,421	8,517	33,976	15,679
Asia, excluding Japan
Disaggregation of Revenue [Line Items]
Total net revenue	3,676	1,846	6,079	5,075
Europe
Disaggregation of Revenue [Line Items]
Total net revenue	4,628	1,325	9,052	4,141
Rest of the World, other than United States, Asia and Europe
Disaggregation of Revenue [Line Items]
Total net revenue	$ 9,892	$ 3,766	$ 17,334	$ 9,014